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ABSTRACT 
The use of hyperkalaemic cardioplegia in cardiac surgery induces depolarised arrest and 
it is currently the gold standard for myocardial protection. Although hyperkalaemia is 
by far the most commonly used clinically, it has been established that depolarised arrest 
has detrimental effects due to sodium and calcium loading. This triggered interest in 
establishing alternative means of cardioplegia.  
Esmolol, an ultra-short acting β-blocker, was found to induce cardioplegic arrest at high 
(millimolar) concentrations and offers improved protection to hyperkalaemic arrest. 
Unlike other alternative cardioplegic agents, esmolol has been used, safely, clinically in 
high doses, which make it clinically relevant. However the arrest by esmolol in 
Langendorff perfused hearts isolated from any catecholamine background cannot be 
explained by its β-blocking mode of action.  The aim is to establish the arresting mode 
of action of esmolol. Pilot data suggested that esmolol has a myofilament desensitising 
as well as an inhibitory effect on the calcium transient (Catr) in the isolated ventricular 
myocyte.  
Esmolol reduced the Catr at high concentration (IC50=~250µm). This was independent 
from the β-blocking effect. The effect on the sarcoplasmic reticulum (SR) was excluded 
by blocking the SR effect using thapsigargin and the negative inotropic effect of 
esmolol was maintained. Using skinned rat myocytes, esmolol did not induce myofibril 
desensitisation. The effect of esmolol on the L-type calcium channels was studied using 
patch clamp techniques. Esmolol was found to inhibit the L-type calcium channels 
(IC50=~450µm). Esmolol also inhibited the fast Na channels (IC50=~150 µm). The 
arrest by esmolol was caused by direct inhibition of the myocardium and not by 
inhibiting the conductive system only using paced Langendorff perfused hearts. It was 
concluded that esmolol induces arrest by blocking sodium and Calcium channels. It was 
last established that, in the Langendorff perfused rat heart, adding a K
+
 channel opener,
adenosine 0.25mM, to esmolol 0.6 mM offers better protection to St. Thomas’ Hospital 
cardioplegia (STH) with 1 hour recovery LVDP of 69±3.7 and 51±4.6 (% of control, 
p<0.01) in 4-hour ischaemia with room temperature multiple infusion cardioplegia.  
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CHAPTER 1. INTRODUCTION 
1.1 Ischaemia in cardiac surgery 
The heart is different from other organs due to the fact that it is continuously beating 
and has very high flow of blood circulating through it (the total blood volume of the 
body passes through the heart in about half a minute). During cardiac surgery, only 
limited procedures can be done on the heart while it is working e.g. off pump coronary 
surgery, mitral valvotomy, etc. To be able to do anything more than that we need to stop 
the heart contracting and empty the heart cavities. This is achieved by clamping the 
aorta and separating the heart from the systemic circulation, which offers a bloodless 
quiescent surgical field. Clamping the aorta, however, results in cessation of blood 
supply to the heart muscle through the coronary arteries, exposing the whole heart to 
ischaemia. This is known as ‘global ischaemia’ and has to be differentiated from 
regional ischaemia in the context of ischaemic heart disease and myocardial infarction. 
Global ischaemia, if prolonged will cause irreversible damage to the heart muscles. 
Different therapeutic measures known as myocardial protection strategies have been 
used to decrease the detrimental effect of global ischaemia on the heart and extend the 
myocardial tolerance to global ischaemia before irreversible damage is sustained. 
1.2 History of cardiac surgery and the development of myocardial 
protection 
The first successful surgical intervention on the heart was reported by Dr. Ludwig Rehn, 
who sutured a puncture wound in the right ventricle of a stab victim in September 1896 
(Rehn 1897). Thereafter, operating on a beating heart became standard practice for heart 
wounds and valve stenosis. However, due to the technical difficulty of operating on a 
beating heart in a very bloody surgical field and in order to perform more complicated 
surgery, it was essential to arrest the heart and stop the blood flow through it. This 
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meant having to deal with the implication of abolishing the cardiac output for the length 
of the procedure, which would cause irreversible brain injury if it lasted for more than 
2-3 minutes in normothermia (Jarcho 1975). The period of clamping the aorta was
extended to 10 minutes by using whole body hypothermia, which was long enough to 
perform the first open heart surgery (Lewis and Taufic 1953) without permanent brain 
damage. The development of cardiopulmonary bypass in 1953 allowed surgeons to 
arrest the heart for longer times without major detrimental effects on the brain 
(Pastuszko and Edie 2004), this is by fully anti-coagulating the blood and draining the 
venous return away from the heart which provides an empty heart in order to operate on 
it. Subsequently, the blood is pumped into an oxygenator and filtered. The blood is then 
returned to the arterial circulation after having been oxygenated and would have 
bypassed the heart and the lungs. This is why it is called the cardiopulmonary bypass. 
By cross-clamping the aorta proximal to the blood return from the bypass machine. The 
heart becomes completely bloodless while maintaining blood supply to the rest of the 
body including the all important brain supply. This offered surgeons longer time to be 
able to operate the heart without having to worry about perfusing the brain. 
Subsequently, it was recognised that inducing arrest and cessation of blood flow to the 
myocardium for longer periods than a few minutes in order to perform complicated 
surgery would expose the heart to irreversible ischaemic damage. Therefore, surgeons 
realised that now the brain is perfused with the cardiopulmonary bypass, it is the heart, 
which needs protection against global ischaemia. Hypothermia was the first and the 
most commonly used method of myocardial protection against ischaemia during 
cardiopulmonary bypass. At this stage the only method to arrest the heart was 
ischaemia-induced arrest where contraction stops due to energy depletion. This method 
was suboptimal because it resulted in faster depletion in energy stores in the cardiac 
myocytes and therefore faster initiation of irreversible injury as demonstrated by Hearse 
and colleagues much later (Hearse et al. 1974). Although this was not the driving 
hypothesis for Melrose’s work, in 1955, he introduced the concept of chemical 
reversible cardiac arrest using a high potassium citrate solution in a canine model in 
order to avoid the problem of air embolisation when working on a beating or fibrillating 
heart (Melrose et al. 1955). This was the first concept of chemical myocardial 
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protection; however, the term “cardioplegia” was first used in 1957 (Lam et al. 1957). It 
became clear soon after that potassium citrate solution proposed by Melrose was shown 
to have detrimental effects on the myocardium leading to myocardial necrosis and 
increased risk of mortality and, consequently, the use of potassium-based cardioplegia 
became unpopular in the late 1950s (McFarland JA 1960). Alternative methods of 
myocardial protection were described, such as intermittent cross-clamp fibrillation and 
coronary occlusion (McFarland JA 1960). However, the use of cardioplegia was 
maintained in Germany with the development of the Bretschneider solution, which was 
Na-poor and Ca-free (Bretschneider et al. 1975). It was used clinically by Sondergaard 
and colleagues (Sondergaard et al. 1975) with success, becoming one of the first 
solutions to be used routinely in clinical practice. Bretschneider published his findings 
almost exclusively in the German literature and, hence, the English-speaking scientific 
communities were generally unaware of this development until much later publications 
in English. In the early 1970s, studies showed that the detrimental effects of the Melrose 
solution were a result of the increased osmolality from the high citrate concentration 
rather than the high potassium levels (Tyers et al. 1975). These results along with others 
revived the concept of cardioplegia in general and hyperkalaemia in particular. Studies 
in the USA by Gay and Ebert (Gay and Ebert 1973) and in the UK by Hearse and 
Braimbridge at St. Thomas’ Hospital (Hearse et al. 1976) lead to the development of a 
cardioplegic solutions based on moderately elevated potassium concentrations that was 
shown to be effective and safe. These solutions were considered as “extra-cellular type 
solutions”, due to their high sodium concentration compared with the Bretschneider 
solution, which has low sodium and classified as an “intra-cellular type solution”. 
Hearse and colleagues continued to optimise their moderately high potassium 
cardioplegia by optimising the potassium and other ionic concentrations such as the use 
of magnesium at optimal concentrations (Hearse et al. 1978) and adding procaine as a 
membrane stabiliser (Hearse et al. 1981). The results of this systematic research, which 
was aimed at optimising the concept of arrest using high potassium was the 
development of the St. Thomas’ Hospital cardioplegia solution No.1 (Table  1.1 
Comparison between the composition of Bretschneider and St. Thomas’ Hospital 
solutions (Modified from Chambers (Chambers and Hearse 2001)). It was first used 
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clinically in 1975 (Braimbridge et al. 1977). The success of this solution in protecting 
the myocardium against global ischaemia and reperfusion injury, identified as the “stone 
heart phenomenon” (Katz and Tada 1972), made it very widely used. Subsequently, the 
original formula of the St. Thomas’ Hospital No.1 solution was slightly modified 
(Hearse et al. 1981) creating the St.Thomas’ No.2 solution, (Table  1.1); it was registered 
with the Federal Drug Authorisation (FDA) in the USA and, rapidly, became by far the 
most widely used cardioplegic solution worldwide and it remains the gold standard 
crystalloid cardioplegic solution. sThe introduction of cardioplegia including the St. 
Thomas’ Hospital solution has definitely changed the practice in cardiac surgery very 
rapidly (Figure  1.1). Up to 1977, ischaemic arrest along with cross-clamp fibrillation 
and hypothermia were the methods of choice for 94% of surgeons in the USA with only 
6% using potassium cardioplegia. By 1982, 99% of these surgeons were using 
cardioplegia (Robinson et al. 1995). From there on the question became; “what is the 
best way to give cardioplegia?” instead of “what is the best way to protect the heart 
during arrest?” Cardioplegia was initially used as a cold crystalloid preparation but in 
the late 70’s, Buckberg developed a potassium cardioplegia mixed with blood as the 
vehicle to improve oxygen delivery and maintain myocardial high energy phosphate 
compounds (Buckberg 1979). The use of blood cardioplegia became popular from the 
mid 80’s (Robinson et al. 1995) and this gradually became the vehicle of choice for 
most surgeons until this day. It is interesting to observe that, despite the advantages of 
blood over crystalloid cardioplegia demonstrated in many small studies, some surgeons 
continue to use crystalloid vehicle (Jacob et al. 2008). 




Table  1.1 Comparison between the composition of Bretschneider and St. Thomas’ 




Bretschneider Bretschneider-HTK STH 1 STH 2 
NaCl 12 15 144 110 
KCl 10 9 20 16 
MgCl2 - 4 16 16 
CaCl2 - 0.015 2.2 1.2 
Procaine-HCl 7.4 - 1 - 
NaHCO3 - - - 10 
K-ketoglutarate - 1 - - 
Histidine - 180 - - 
Histidine HCl - 18 - - 
Tryptophan - 2 - - 
Mannitol 239 30 - - 







Osmolality 320 310 300 324 
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Recently, a large meta-analysis of blood compared to crystalloid cardioplegia was 
conducted; reviewing 10 randomised clinical trials and over 800 patients. This 
demonstrated a marginal superiority of blood cardioplegia over crystalloid cardioplegia 
in terms of low cardiac output syndrome and rise in cardiac enzymes. However, the 
incidence of perioperative myocardial infarction and death were the same (Guru et al. 
2006). This marginal advantage might explain the failure of blood cardioplegia to 
totally dominate the practice in the same way that St. Thomas’ cardioplegia did in the 
early 80’s.  
 
 
Figure  1.1. Myocardial Protection Method: Frequency in the USA (modified from 
Robison and colleagues (Robinson et al. 1995)) 
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1.3 Ischaemia and cardioplegia 
As mentioned previously, global ischaemia cannot be avoided in order to operate on a 
bloodless heart and in order to operate safely on the diseased heart, it is important to 
understand the effect of global ischaemia and try to minimise its damaging effect. Organ 
ischaemia can be universally defined as a deficiency in the blood supply (and thus 
oxygen and nutrients) to an organ to meet its physiological demand in order to function 
normally (Hearse DJ 1994). In the heart, the normal function is dependent on a 
continuous supply of high-energy phosphate compounds, particularly ATP. 
Approximately 60-70% of ATP is utilised by the contractile apparatus, while up to 25% 
is utilised by the ion translocating systems in the myocytes (Opie 1991). Since high-
energy phosphate compounds are not stored in the heart, induction of ischaemia will 
rapidly use available ATP and this will result in gradual reduction in contractility with 
eventual arrest of the heart. Relatively short durations of ischaemia are associated with 
reversible injury, whereby early reperfusion will eventually return the myocardium to 
normal. However, longer periods of ischaemia induce irreversible injury associated with 
low levels of high-energy phosphate compounds and this will lead to cell death and 
myocardial necrosis (Figure  1.2). The concept of cardioplegic arrest is to prevent high-
energy compound utilisation and delay the onset of irreversible injury. It is important to 
understand, however, that a cardioplegic solution will never abolish the effect of 
ischaemia totally; therefore the aim is to continue improving the cardioplegic solutions 
used in cardiac surgery, along with other myocardial protection strategies, to delay 
ischaemic injury and allow longer and more complicated surgeries to be performed 
without residual detrimental effect on the myocardium (Figure  1.3). Therefore, 
achieving reperfusion as soon as possible will always be the single most essential 
component of the protection process. It is also important to distinguish between regional 
ischaemia in the context of ischaemic heart disease and global ischaemia in cardiac 
surgery. Patients who are undergoing cardiac surgery for ischaemic heart disease 
already have an element of regional ischaemia, which could already have resulted in 
irreversible damage to parts of the myocardium after a myocardial infarction episode 
pre-operatively. Exposing these hearts to additional periods of global ischaemia while 
performing bypass surgery is unavoidable; the aim of cardioplegia is to delay the onset 
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of irreversible damage caused by global ischaemia in cardiac surgery on an already 






Figure  1.2 Schematic of the cellular mechanism of ischaemic injury over time 
(modified from Hearse and colleagues (Hearse et al. 1981)) 
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Figure  1.3 Schematic graph explaining the concept of myocardial protection associated 
with cardioplegia in prolonging the period of reversible ischaemia. 
1.4 Pathological changes of reversible vs. irreversible ischaemia 
Within seconds of the development of severe ischaemia, the myocardial cell switches 
from aerobic to anaerobic metabolism. This leads to reduced production of ATP and the 
accumulation of inorganic phosphate and lactic acid in the cell causing intracellular 
acidosis. Myocytes are very sensitive to inorganic phosphate and cellular acidosis and 
this will lead to loss of contraction within 2 minutes. Over the next few minutes, 
reversible ultra-structural changes occur and become visible using electron microscopy; 
these changes include glycogen depletion, cellular and mitochondrial swelling,
myofibrillar relaxation, and margination of nuclear chromatin. If ischaemia persists 
(usually between 20 to 40 minutes), amorphous mitochondrial
 
densities, sarcolemmal 
disruption and membrane structural changes are seen (Schoen FJ 2003). These 
presentations are irreversible and considered as evidence of necrosis. Figure  1.2 
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poor, a condition described by the famous American surgeon Denton Cooley as the 
“stone heart” was shown to occur (Katz and Tada 1972). The stone heart, which is 
invariably fatal, became a challenge to the biochemists in order to find a solution. It was 
subsequently shown to be a result of reduced myocardial ATP content leading to 
irreversible ischaemic contracture caused by excessive calcium loading (Cooley DA 
1972). 
In summary, reversible injury to the myocytes starts very shortly after the onset of 
ischaemia; with more prolonged ischaemia the injury becomes irreversible. The most 
effective way in preventing irreversible injury is by resuming perfusion as soon as 
possible. However, when early reperfusion is not possible, there are other factors and 
interventions, which could delay this injury process and in the context of cardiac 
surgery, one of the most effective ways to delay this injury is to induce cardioplegic 
arrest. In order to understand the principles involved in inducing myocardial arrest, it is 
important to have detailed understanding of the physiological mechanisms involved in 
triggering and generating contraction in the myocardium or what is known as excitation 
contraction coupling. 
1.5 The physiology of excitation-contraction coupling 
Excitation-contraction coupling is a complex process that involves ionic changes 
regulated by the cell membrane in the myocardium and generating electrical changes in 
the cell membrane potential. These changes, which are known as the action potential are 
the linking switch between the excitation signal and the contractile effect. The following 
will briefly describe this process. 
1.5.1 The membrane potential at rest 
The maintenance of ionic distribution across the membrane at rest is responsible for the 
resting membrane potential (Em). The difference in ionic concentrations 
and conductance is responsible for this value, which can be calculated using 
Goldman-Hodgkin-Katz (GHK) equation . 
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Em = ln(PK + PNa +PCl ) 
Where Em = membrane potential 
Pion = permeability for the ion 
aIONo = extracellular activity (the concentration in free form) of the ion 
aIONi = intracellular activity of the ion. 
R = gas constant  
T = temperature in kelvins  
F = Faraday's constant  
z = valency of the ion  
The advantage of the GHK equation is that it can calculate the membrane potential 
when there is more than one permeable ion, which is very relevant to the cardiac 
myocyte. While the more simplistic Nernst equation calculates the Em in a model when 
a membrane is impermeable to one ion, which is potassium in this case; therefore it is 
assuming that the membrane is completely permeable to the rest of the other ionic 
species (Katz 1992). 
Em = ln(PK 
   ) 





z=1 and a membrane fully permeable to the ion, p=1, at 37
o
C the equation can be
simplified to  
Em = 61.5 ln(
   ) 
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In the resting cardiac myocyte where [K
+
]o is     5.4 mM and the [K
+
]i  is    110 mM, the
potassium activity is about 4 and 100 mM respectively. Em therefore for a membrane 
that is fully permeable to K
+
 at these activities is Em=61.5 log (4/100) = -86 mV. At rest
the membrane potential is close to -80 mV, which suggests that the permeability to 
potassium at these concentrations is near 1 (fully permeable) and possibly less 
permeable to other ions. Intracellularly, K
+
 is the principal cation, and phosphate and





 predominate. It is important, however, to bear in mind that the cell
membrane is not a simple semi-permeable membrane (Katz 1992); the ionic 
permeability of this membrane is determined by sophisticated mechanisms, which 
involves the activity of certain ionic channels, pumps and other membrane exchanging 








 exchanger current and the IKr inwardly
rectifying K
+
 current (Bers 1991).
The resting period in the cardiac cycle is responsible under physiological conditions for 
the diastolic ventricular phase, which allows the heart to fill with blood, ready to eject 
during the next contraction. This phase is called phase 4 during the membrane action 
potential (Figure  1.4) and is particularly important in cardiac surgery because the heart 
is arrested during this phase for a long period. Furthermore, the membrane potential 
during cardioplegic arrest is one of the factors that determine the effectiveness of an 
arresting agent in myocardial protection as explained in detail later. 
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Figure  1.4 Schematic of cardiac myocyte and the membrane action potential. 
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1.5.2 The rapid depolarisation phase 
During excitation and the changes in the action potential the permeability of the 
membrane to the various ionic species is constantly changing due to the activation of 
various channels, pumps and exchangers. Therefore, the Nernst equation, which takes 
into account a single ion and single permeability, becomes inadequate to calculate the 
Em. The GHK equation, despite taking into account more than one ionic species, also 
has its limitations during the action potential as it calculates Em in the steady state 
without any changes in the permeability of the membrane via the mechanism mentioned 
earlier (Katz 1992).  
At the resting Em all the fast Na
+
 channels are closed but excitable to electrical
stimulation to the membrane by the conducting system or by a pacemaker. This results 
in immediate and simultaneous opening of these channels, allowing a rapid entry to Na
+
inside the myocyte and making the membrane more permeable to Na
+
(Niedergerke and







]i according GHK equation (above) and the
membrane polarity changes to +20mV (close to Na
+
 equilibrium potential of around
+50mV). This phase is called phase 0 (Figure  1.4) and is responsible for initiating
contraction in the cardiac cycle. After the peak of phase 0 there is a small downward 




 and this is called
phase 1 (Figure  1.4) (Opie 1991; Katz 1992).  
The fast Na
+
 channels are double-gated according to the Hodgkin-Huxley model. They
are complex proteins embedded in the cell membrane and are formed of two types of 
protein subunits, α and β (Hodgkin et al. 1952; Katz 1992). The α-subunit assembles to 
form the functional core of the channel. The α-subunit protein is sufficient to enable the 
cell to conduct Na
+
 in a voltage-gated way, without the β-subunits. The β-subunits are
responsible for the channels altered voltage dependence and cellular localisation (Katz 
1992). The α-subunit (Figure 1.5, A,B) has four repeated domains I-IV, each containing 
six membrane-spanning regions, labelled 1-6. Region 4 acts as the channel's voltage 
sensor (Katz 1992). The high voltage sensitivity of the channel is due to the strictly 
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conserved amino acid sequence in this sensing region with the positively charged amino 
acid arginine and lysine around the membrane embedded part. This arrangement enables 
the sensor to move within the membrane bilayer as membrane potential changes (Katz 
1992). The Na
+
 channels structure is an example of a voltage-dependent channel 
described by the Hodgkin and Huxley principle (Hodgkin et al. 1952). The function and 
the state of these channels are determined by the position of two gates; the activation 
and inactivation gates (Figure 1.5, B and C). During the propagation of the action 
potential the sensing region is stimulated by a change in membrane voltage. This region 
moves toward the extracellular side of the cell membrane, displacing the activation gate 
(region 6) and opening the pore of the channel. This leads to further depolarisation of 
the membrane potential, which opens more activation gates at a very fast rate (0.1-0.2 
ms) (Niedergerke and Orkand 1966), closer to the Na
+
 equilibrium potential of +50 mV 
(Katz 1992). As the membrane potential depolarises, over 1 ms later, the inactivation 
gate formed by links between domains III and IV closes by forming a tethered plug to 
the intracellular side of the channel gap, thereby terminating the INa current. The 
channels then remain refractory in the inactive state until these inactivation gates reopen 
much later in the action potential when repolarisation is restored. At membrane 
potentials between -20 and -60 mV the two gates can become partially opened at the 
same time allowing constant slow entry of the Na
+
 inside the cell, generating what is 
known as the Na
+
-window current.  
The selectivity of the channel to Na
+
 is due to the negatively charged amino acid 
sequence in the extracellular part of the entry pore, which is narrowed down (0.3-0.5 
nm) by the selectivity filter in regions V and VI. This amino acid sequence attracts the 
positively charged ions and keeps the negatively charged ions out, allowing only one 
Na
+





cannot fit and enter this channel. Also, other smaller size cations do not interact well 
with the negatively charged glutamic acid lining the pore (Opie 1991). Agents that 
inactivate these channels or block their pores can induce arrest and hence can be used as 
cardioplegic agents.  





Figure  1.5 the structure of the alpha subunit of fast voltage gated Na
+
-channels; A, 
the linear structure; B, the three dimensional structure; C, the channel opened and 
closed (modified from http://courses.cm.utexas.edu/jrobertus/ch339k/overheads-
2/ch12_volt-gated-chan.jpg)
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1.5.3 The plateau phase  
During the plateau phase (phase 2), the action potential stabilises despite many currents 
being activated, such as the outward K
+





 exchanger current, and others. This is because these currents are 
balanced by an inward current of Ca
2+
 through the L-type calcium channels. This 
current makes the cardiac action potential unique and is responsible for the refractory 
period of the cardiac myocyte, which ensures effective contraction and prevents 
arrhythmias. Additionally, it provides the transient rise in intracellular Ca
2+
 
concentration essential for contraction (Bers 1991). Inhibitors of these channels can 
inhibit contraction and therefore can be used as cardioplegic agents (Yamamoto et al. 
1983). The mechanism of calcium channels in relation to cardiac arrest requires a 
detailed description of their mechanism of action. Therefore the calcium channels have 
relevant importance and described in details next. 
The effect of Ca
+
-channels was discovered accidentally in the Biophysics lab at the 
University College London in 1952 by Bernard Katz and colleagues (Fatt and Katz 
1953). While investigating the membrane potential using voltage clamping studies in 
large muscle cells of crab and crayfish; they, unexpectedly, found electrical responses 
that persisted in sodium-free media, when Na
+
 was replaced by tetrabutylammonium 
(TBA). One speculative of mechanism to explain this current was a calcium-mediated 
or magnesium-mediated inward current. In the heart, the plateau phase was found to be 




 (Wray et al. 2004). This current 
was attributed to what was mistakenly called the dihydropyridine receptors (DHPRs) 
after the calcium antagonist nifedipine (Dolphin 2006). These were later shown to be 
voltage channels to Ca
2+
 and the cardiac types were identified as the L-type and the less 
significant T-type (Bers 2002). The L-type channels are voltage-gated pores localised in 
the cell membrane. They become activated at Em between -50 and -10 mV allowing 
Ca
2+
 inside the cell according to the Hodgkin and Huxley principle (Hodgkin et al. 
1952). The biochemical structure is formed of a complex protein structure with four or 
five subunits. The 1 subunit of 190-250 Kilo Dalton is the largest subunit and it 
incorporates a conduction pore similar to that of the sodium channels; it contains a 
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voltage sensor and gating apparatus. The 1-subunit of voltage-gated calcium channels 
is organised into four homologous domains (I-IV) with six transmembrane regions in 
each. As in sodium channels, the fourth region is the voltage sensor and the selectivity 
filter is formed by the pore loop between regions 5 and 6. The selectivity of the channel 
to Ca
2+
 is due to changes of only three amino acids in the pore loops in domains I, III, 
and IV from the sequence in the sodium channels. An intracellular -subunit and a 
transmembrane, disulphide-linked 2-subunit complex are components of most types 
of calcium channels. A -subunit was also found in skeletal muscle calcium channels 
and related subunits are expressed in heart and brain. Although these auxiliary subunits 
modulate the properties of the channel complex, the pharmacological and 
electrophysiological diversity of calcium channels arises primarily from the existence of 
multiple 1-subunits (Opie 1991; Catterall 2000).  
 
1.5.4 The repolarisation phase 
During phase 3 of the action potential (Figure  1.4), the calcium channel current (ICa,L) 
declines due to the inactivation of the channels and an ongoing outward K
+
 current via 
the slow delayed rectifier (IKs). This shifts the Em to more negative values, activating 
other K
+
 channels like the rapid delayed rectifier. These channels are sensitive to ATP 
and are referred to as the ATP-sensitive potassium (KATP)-channels (Opie 1991). 
Activating KATP-channels pharmacologically will result in shifting the resting Em closer 
to the K
+
 equilibrium potential, leading to hyperpolarisation. This makes the sodium 
channels less excitable and could result in cardiac arrest. KATP-channel activators, like 
pinacidil, have been used through this mechanism to induce cardioplegic arrest using 
(Jayawant and Damiano 1998). Due to the importance of these channels in inducing 
cardioplegic arrest they are described in detail below.  
 (KATP) channels were first described by Noma in the myocardium (Noma 1983). When 
they are activated they generate a small K
+





. Eventually, the L- type calcium channels become inactivated 
and repolarisation is re-established with this polarising current. The KATP-channels are 
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inhibited by the physiological intracellular [ATP] of around 3-4 mM (Khairallah and 
Mommaerts 1953). When [ATP] drops below 1 mM these channels open allowing high 
efflux of K
+
. At rest the sarcolemma is a semi-permeable membrane to K
+
, shifting the
resting membrane potential closer to K
+
 reversal potential of -90mV. However, due to a
small inward leak current of Na
+
, this potential is offset by +10 mV to -80mV, which is
the physiological resting membrane potential. The activation of KATP-channels by the 
KATP openers generates an outward K
+
 current offsetting the small Na
+
 current and
hyperpolarising the membrane closer to -90mV. An arrest induced by these agents is 
called hyperpolarised arrest, which has its advantages in the use of cardioplegia. 
1.5.5 Calcium-induced calcium-release 
The rise in intracellular [Ca
2+
] during the plateau phase of the action potential leads to
activation of the ryanodine receptors (RyR) due to the close localisation of these 
channels in the dyadic junction in the T-tubules of the sarcolemma (Bers 2002). RyR 
activation releases significant amounts of Ca
2+
 from the sarcoplasmic reticulum (SR);
and this process is known as calcium-induced calcium-release. The sensitivity of the 
RyR to Ca
2+
 on its cytosolic side is responsible for the positive feedback mechanism in
RyR activation, and explains the fast non-linear rise in the intracellular calcium 
transient (Catr) (Bers 1991). A cluster of RyR in the cytosol is activated in response to 
localised increase in [Ca
2+
] resulting in a spatiotemporally-restricted rise in cytosolic
Ca
2+
 that can be visualised as a “calcium spark” (Cheng et al. 1993). There are different
isoforms of the RyR; RyR1 is primarily expressed in skeletal muscle, RyR2 in the 
myocardium, RyR3 is widely expressed but mainly in the brain and there is RyR4 
expressed only in fish (Zucchi and Ronca-Testoni 1997). The function of the SR is to 
magnify the intracellular rise of calcium as a response to the activation of the L-type 
calcium channels creating Catr. This results in more cytosolic Ca
2+
 available for the
myofilaments to induce contraction as a response to the excitation stimulus. 
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1.5.6 Cross-bridging and myofilaments contraction  
The interaction between the thick (myosin) heads and thin (actin) myofilaments is 
known as crossbridging and is translated into shortening in the myocytes. These 
myofilaments are in close contact with the sarcolemma, which invaginates at the levels 
of the Z-lines forming the T-tubules (Figure  1.6, A). Myosin heads binding to actin is 
regulated by the crossbridge regulatory proteins; the first is troponin (Tn) with the three 
subunits C, I and T, and the other protein is tropomyosin, which separates the actin from 
the myosin heads and resides in the cleft between the two actin strands (Figure  1.6, B). 
When the intracellular ionised Ca
2+




 -release phase, 
TnC binds to Ca
2+
 inducing conformational changes to the troponin complex and 
causing TnI to dissociate from actin. Tropomyosin then becomes dissociated from the 
actin cleft revealing myosin binding sites. These sites allow the crossbridges to form 
between the myofilaments, resulting in tension and shortening of myocytes (Solaro and 
Rarick 1998).  
In summary, myocardial contraction is a staged process involving a complex interplay 
between ionic changes occurring during the action potential and the contractile 
mechanism of the sarcomere. This staged process enables us to understand the various 
mechanisms of contraction and by, targeting these stages and mechanisms 
pharmacologically we can induce effective cardioplegic arrest. We aim next to define 
cardioplegia and systematically review the mechanisms of various cardioplegic 
solutions available experimentally and clinically based on the stages of excitation 
contraction-coupling. 
1.6 Cardioplegia 
The term “cardioplegia” was first used in 1957 to define the elective rapid and 
reversible chemical arrest of the heart in order to perform cardiac surgery (Lam et al. 
1957). However, cardioplegia should also aim to offer protection to the heart against 
ischaemia among other things addressed below. 
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1.6.1 The aims of cardioplegia 
The aim of using cardioplegia in cardiac surgery is to allow the surgeon to operate on a 
quiescent flaccid empty heart and protect it from the consequences of global ischaemia 
and reperfusion caused by aortic cross clamping to provide a bloodless surgical field. 
Although there are many agents capable of inducing cardiac arrest, an effective 
cardioplegic arrest solution should be able to meet the following criteria:  
 
 
Figure  1.6 The sarcomere structure, A, a schematic of a sarcomere, B, the interaction 
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I. Arrest: A rapid and effective induction of diastolic arrest to keep the 
myocardium relaxed and to minimise cellular use of ATP. 
II. Myocardial protection: Protective effects to delay the onset of irreversible 
injury caused by global ischaemia and to limit the extent of reperfusion injury. 
III. Reversibility: Readily-reversible cardioplegic effects on washout for quick 
resumption of heart function, to enable early weaning off cardiopulmonary 
bypass. 
IV. Low toxicity: A short half-life with no toxic effects on other organs after 
cessation of cardiopulmonary bypass. This is especially important if high 
concentrations of the pharmacological agent are required to achieve arrest. 
1.6.2 Variation of cardioplegic solutions 
Cardioplegic solutions have been widely used for more than 30 years. This has triggered 
considerable research work to establish the optimal cardioplegic solution and the best 
way to introduce it into the heart. Although hyperkalaemic cardioplegia remains by far 
the main concept used, the ongoing work to establish the best way to introduce it 
resulted in different preparations and methods of delivery. The following list is aimed to 
include all solutions used clinically or experimentally based on the following criteria. 
1 Vehicle: cardioplegia can be given as a crystalloid (asanguineous) solution 
(Chambers and Hearse 2001) or autologous blood (Buckberg 1979). 
2 Temperature: This can be cold (4°C), patient’s temperature (35-37°C), Tepid 
(29°C), room temperature (23-25°C), or as a “hot shot” at the end, known as 
terminal cardioplegia. Although the term “hot shot” can vary in practice from blood 
based high K
+
 cardioplegia at higher temperature (37
o
C) to a warm blood solution 
with added substrate the principle is to give it as a treatment after ischaemia near the 
end of the cross-clamp period, just before reperfusion (Imura and Suleiman 2008). 
The aim is to restore the cellular high energy compounds before contraction. This 
strategy was shown to have advantages over standard cold blood cardioplegia during 
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ischaemia only in patients undergoing CABG (Caputo et al. 1998). The same group, 
however, demonstrated that these findings can vary between the chronic ischaemic 
and the hypertrophied myocardium. Ascione and colleagues demonstrated that there 
is no clear advantage in adding a “hot-shot” in patients with hypertrophied left 
ventricle undergoing aortic valve surgery (Ascione et al. 2008). 
3 Methods of delivery: The most widely used method of delivering cardioplegia is 
through an antegrade perfusion via a cannula inserted into the aortic root, down the 
coronary arteries. This, however, becomes difficult in aortic regurgitation as the 
solution could leak into the LV cavity. To overcome this problem, retrograde 
perfusion can be used. It was first described in 1956 (Lillehei et al. 1956) and it is 
administered via a cannula in the coronary sinus through the coronary veins back 
into the coronary arteries. Other potential advantages of retrograde perfusion 
include, in principle, better delivery to the territories supplied by occluded coronary 
arteries in ischaemic heart disease but there is no convincing evidence in the 
literature to support this (Allen et al. 1995). Retrograde cardioplegia can also be 
administered easily without getting in the way of the surgeon, especially in the 
context of mitral valve surgery where antegrade cardioplegia requires repositioning 
of the heart and interrupting the surgery during each administration. The main 
disadvantages of retrograde cardioplegia however include its poor perfusion to the 
right ventricle and therefore it offers suboptimal right ventricular protection (Allen 
et al. 1995). Another disadvantage is the technical difficulty in introducing the 
cannula via the right atrium in the coronary sinus and the potential injury to the 
coronary sinus. 
4 Infusion interval: Cardioplegia is usually given intermittently but occasionally it 
can also be given continuously, usually retrogradely. 
5 The mode of arrest: The above criteria address the variable methods of introducing 
the cardioplegic solution into the patient and have been mainly used with 
hyperkalaemic cardioplegia. Considerable clinical and experimental research has 
been conducted in order to establish the best way to administer hyperkalaemic 
cardioplegia, in terms of temperature, vehicle and methods of perfusion. This has 
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generated a large volume of literature, which can, sometimes, be confusing (Jacob et 
al. 2008); however, this multitude of studies does suggest that improved 
cardioplegia is still required. The advantages of simply further modifying the current 
techniques of hyperkalaemic cardioplegia are likely to be marginal. Thus, new 
concepts of arrest that may provide potentially beneficial alternatives to 
hyperkalaemia are required, for any chance of achieving significant improvement 
over the widely accepted hyperkalaemic arrest (Fallouh and Chambers 2008). The 
following paragraph will discuss the potential modes of action of arresting agents in 
detail and try to describe the disadvantages and disadvantages of each. 
1.7 Mechanism of inducing cardioplegic arrest 
In order to induce chemical arrest, the arresting agent should be aimed at cellular targets 
in the cardiac myocytes or the conduction tissue, which takes part in the excitation 
contraction coupling. This can be summarised into the following groups (Figure  1.7) 
a) Inhibiting the fast sodium current (INa) to prevent the propagation of the 
myocardial action potential. 
 Extracellular hyperkalaemia (eg. STH) 
 Sodium channel blockers (lidocaine, procaine, tetrodotoxin (TTX)) 
 KATP-channel openers (pinacidil, adenosine) 
b) Inhibiting calcium activation of the myofilaments to prevent myocyte 
contraction. 
 Zero extracellular calcium (Bretschneider solution (Bretschneider et al. 
1975) 
 L-type calcium-channel blockers (high magnesium, diltiazem, verapamil) 
c) Direct myofilament inhibition (myofilament Ca2+ desensitisation with 2,3- 
butanedione monoxide (BDM) 
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1.7.1 Inhibiting the fast sodium current 
1.7.1.1 Hyperkalaemia 
Elevation of the extracellular potassium concentration ([K
+
]e) to 10-40 mM will shift Em 
from about -85 mV to a range between -65 to -40 mV, according to the GHK constant 
field equation. At potentials above -65mV, most of the fast sodium channels that are 
responsible for phase 0 of the action potential become inactive. At higher [K
+
]e, leading 
to Em over -40 mV, the L-type calcium channels are activated, which will lead to inward 
calcium flux and calcium loading. Therefore, it is important to use [K
+
]e within the 
range that inactivates the fast sodium channels without activating the L-type calcium 
channels. Hyperkalaemia induces arrest by shifting the resting Em away from the 
physiological polarisation voltages; thus it was termed as depolarised arrest. In order to 
determine the optimal [K
+
] to induce arrest in the rat hearts, Hearse and colleagues 
found that [K
+
] concentrations between 16 to 20 mM, which could induce arrest without 
inducing too high coronary resistance and low coronary flow. (Figure  1.8) (Hearse et al. 
1975). This was, interestingly, consistent with the values extrapolated from the GKH 
equation (Figure  1.9).  
Gay and colleagues used much higher [K
+
] of 40 mM in their hyperkalaemic 
cardioplegia (Gay and Ebert 1973) earlier. Thereafter, numerous studies by Hearse and 
colleagues were conducted to further improve hyperkalaemic cardioplegia by 
optimising temperature (Hearse et al. 1975), mode of delivery and the additives to high 
potassium (Hearse et al. 1976). Additional examples explored the value of additives 
(Mg
2+ 
 (Hearse et al. 1978), high energy phosphate compounds (Robinson et al. 1984) 
(Robinson et al. 1987) and procaine (Hearse et al. 1981)) to cardioplegia; in “working 
mode” perfused rat hearts, subjected to 30 minutes of normothermic ischaemia, these 
compounds improved recovery of aortic flow from around 30% for hyperkalaemia only 
to over 93% with cumulative effect of Mg
2+
, ATP, procaine and creatine phosphate 
(Hearse et al. 1976). Ultimately the extensive characterisation strategies to optimise 
cardioplegia paired with the clinical insight and the need to deliver an effective solution 
resulted in the development of the St. Thomas’ Hospital cardioplegic solution No.1 
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(STH1) in 1975. This solution was designed to achieve a balance between simplicity 
and maximum myocardial protection (Hearse et al. 1981). STH1 contains Mg
2+
 and 
procaine (but did not contain other agents like ATP and creatine phosphate) and did not 
have any buffering capacity for the purpose of simplicity (Hearse et al. 1981). Further 
work and development were made on STH1 solution, which resulted in the development 
of the St. Thomas’ Hospital cardioplegic solution No.2 (STH2) (Jynge et al. 1981). In 
STH2, [K
+
] was decreased from 20 to 16 mM, [Ca
2+
] was also reduced to 1.2mM, a 
buffer was added in the form of NaHCO3 and procaine was removed to enable the 
solution to be registered with the FDA, which does not recognise procaine for human 
use (Table  1.1). Depolarised arrest by STH1 and STH2 is proven to be an effective, safe 
and reliable means of arresting the heart during heart surgery, explaining its wide use. 
However, shifting Em to voltages close to -50mV makes the fraction of activated and 
inactivated INa channels equal in the steady state. This generates an inward window 
current of Na
+
 (at Em between -60 and -15mV) during the period of ischaemia and 
depolarisation. Ischaemia can further increase the Na
+










-ATPase (assisted by hypothermia (Lahorra et al. 1997)). As a 
result the myocyte becomes loaded with Na
+
, which causes increased osmolality and 
cell oedema. At reperfusion, the high intracellular Na
+





which plays a major role in heart failure patient (Terracciano et al. 2007), becomes 
active in reverse mode and the Na
+
 is exchanged with Ca
2+
 (Satoh et al. 1995; Satoh et 
al. 2000), which lead to Ca
2+
 loading. Higher [K
+
] like the Gay solution (Gay and Ebert 










 loading are features of ischaemia and although hyperkalaemia might, it 
can result, in Na
+
 loading (Schepkin et al. 1999). This is possibly by the effect of 
preventing prolonged ischaemia and reinstating perfusion as soon as possible.  
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Figure  1.8 The relationship between [K
+
] and heart rate (squares) and coronary 
flow (circles), in the isolated rat hearts, data presented as Mean ± SEM. (Modified 

























Figure  1.9 Cell membrane potential in relation to extra-cellular potassium (modified 
from (Bers 1991)) 
[K+] mM 
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1.7.1.2 Na+ Channel blockers 
INa blockers like lidocaine can arrest the heart by inhibiting the action potential at phase 
0 and has proven to be an effective arresting agent (Asano et al. 2003; Dobson and 
Jones 2004; Yamaguchi et al. 2007). Additional protection was also demonstrated in a 
long term preservation with procaine when it was added to hyperkalaemic cardioplegia 
(Hearse et al. 1981) and consequently was included in STH1 (Table  1.1). Blocking the 
INa current with these agents maintains Em close to the resting potential, inducing a 
“polarised arrest”. This was demonstrated in a long-term preservation study by Snabaitis 
and colleagues (Snabaitis et al. 1997) in which rat hearts were stored for 5 hours at 
7.5
o
C and Em was measured throughout ischaemic storage using sharp electrode on the 
surface of the heart. Three groups of rat hearts were arrested using hyperkalaemia (16 
mM), the Na-channel blocker tetrodotoxin (TTX) or Krebs-Henseleit Buffer (KHB) 
then were stored at 7.5
o
C for 5 hours. Em was measured during the 5 hour cold 
ischaemia period. Em in the hyperkalaemia group dropped instantaneously to -50mV 
and remained throughout the period of ischaemia while the TTX group remained at 
around -70mV. The KHB group started at -70 mV and depolarised during ischaemia to -
50mV (Figure  1.11). At membrane potentials close to -70 mV, the Na
+
 ‘window’ 
current is absent (McAllister et al. 1975; Attwell et al. 1979).  
































Contracture, reperfusion injury, cell death
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Figure  1.11 Cardiac Em recorded every 15 minutes during 5 hours of hypothermic 
(7.5°C) ischemic arrest with KHB( ), hyperkalaemic arrest ( ), and TTX arrest ( ). 
(figure modified from Snabitis and colleagues (Snabaitis et al. 1997)) 
 
Van Emous and colleagues (Van Emous et al. 1997) investigated the role of the fast 
sodium channels in sodium loading using nuclear magnetic resonance (NMR) studies. 
They demonstrated that in hearts pre-treated with lidocaine, the intracellular Na
+
 
concentration rise during normothermic ischaemia (30 min) was inhibited compared 
with global ischaemia alone. Myocardial ATP levels were higher and recovery of 
developed and end-diastolic pressure with lidocaine. They concluded that the fast 
sodium channels are involved in the Na
+
 loading during ischaemia and that blocking 
these channels pharmacologically could inhibit Na
+
 loading. On the other hand, 
Schepkin and colleagues (Schepkin et al. 1996; Schepkin et al. 1999) demonstrated, 
using NMR, that the fast Na
+
 loading, which takes place during ischaemia and can only 
be partially reduced in depolarised cardioplegic arrest; single dose hyperkalaemic 
cardioplegia followed by normothermic ischaemia in the Langendorff rat heart resulted 
in onset of increased [Na
+
]i after 20 min and after 51 min there was a significant rise in 
[Na
+
]i but this remained significantly less in than the ischaemia alone group. However, 
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multidose hyperkalaemic cardioplegia at 17 minutes interval resulted in very little Na
+
 
loading after 51 minutes of normothermic ischaemia in the rat heart (Schepkin et al. 
1999).  
It is difficult to be certain that the mechanism behind any improved protection against 
ischaemia offered by Na
+
 channel blockade over the traditional hyperkalaemic 
cardioplegia is by inhibition of Na
+
 loading as we are not aware of any NMR studies 
that directly compares polarised cardioplegic arrest by Na
+
 channel blockade with 
depolarised arrest by hyperkalaemia. However, it is reasonable to assume that direct Na
+
 
blockade would offer a feasible alternative to depolarised arrest possibly by reducing 
depolarisation-induced Na
+
 loading. This polarising arrest effect with INa blockade has 
since been explored further and was shown to be effective at different temperatures but 
36
o
C cardioplegia in the Langendorff perfused rat hearts was the optimal 
temperature(Asano et al. 2003). It was also used with other additives such as adenosine 
(Dobson and Jones 2004) or magnesium (Yamaguchi et al. 2007) in experimental 
studies.  
Despite the advantages of lidocaine over hyperkalaemia demonstrated in the 
experimental studies, the use of Na
+
-channel blockade has had minimal clinical uptake 
bearing in mind that lidocaine is already used clinically as a local anaesthetic and an 
anti-arrhythmic agent at lower doses. One problem is that lidocaine clearance is 
dependent on hepatic and renal activity (which is reduced for varying periods as a result 
of low perfusion during cardiopulmonary bypass), so doses of lidocaine sufficient to 
induce arrest may lead to accumulation of the drug and its metabolites in the body after 
reperfusion and cause potential arrhythmic and neurological toxicity (Waller 1981). 
Yamaguchi and colleagues (Yamaguchi et al. 2007) showed that the lidocaine 
concentration required to effectively arrest an in vivo dog heart was 1.4 mM (in 
combination with elevated (5.5 mM) magnesium). The plasma concentration in the 
peripheral circulation was found to be 0.08 mM at the time of weaning from bypass; this 
is much higher than the upper safety margin defined as 0.03-0.04 mM (Foldes et al. 
1960). The study by Yamaguchi and co-workers (Yamaguchi et al. 2007) was the first 
to look at the toxic effects of high doses of Na
+
-channel blockers as cardioplegic agents 
(Fallouh and Chambers 2007) 
CHAPTER 1: INTRODUCTION 
51 
1.7.1.3 K+ channel activation 
Drugs that open K
+
-channels in the resting cell will tend to shift Em closer to the 
potassium equilibrium potential (about -90 mV) under steady-state conditions (Cohen et 
al. 1993), thereby inducing a hyperpolarised state. Em is thus shifted away from the 
activation threshold of the fast Na
+
 channels and should lead to cardiac arrest by 
inhibiting phase 0 of the action potential, making K
+
-channel openers potential 
cardioplegic agents. Pinacidil, which targets the ATP-sensitive K
+
 (KATP) channels, was 
found to be superior to STH as a cardioplegic agent in an in vivo pig heart model 
(Jayawant et al. 1999). More recently, activation of KATP channels was shown to reduce 
myocyte Ca
2+
 loading and to reduce post-ischaemic contracture in the isolated myocytes 
(Baczko et al. 2005). However, the efficacy of pinacidil to induce cardiac arrest has 
been questioned (Walgama et al. 2000); our group has shown that, even with very high 
concentrations, pinacidil failed to induce arrest in aerobically-perfused rat, rabbit or 
guinea pig hearts (with species-dependent concentration effects). Furthermore, the 
prolonged electrical and mechanical activity with pinacidil cardioplegia in the rabbit 
hearts (~900 seconds and ~200 seconds, respectively) suggests arrest was ischaemia-
induced rather than by direct effects on the KATP channels (Jayawant and Damiano 
1998). Additionally, it was found that, with pinacidil cardioplegia, there is an increase 
in oxygen consumption post-ischaemia (Lawton et al. 1997) compared with STH group 
in the rabbit hearts; this was explained by the oxygen demand for high reparative 
processes of viable myocytes or to a higher oxygen debt generated during ischaemia. 
The questionable ability of pinacidil to induce arrest as well as the increased oxygen 
demand at reperfusion presents a significant limitation to pinacidil cardioplegia. More 
importantly, however, the pinacidil half-life in a healthy human subject was shown to be 
>2 hours (Ward et al. 1984). This slow clearance, together with a narrow safety margin 
in the micromolar range (Kowaltowski et al. 2001), means that the high concentrations 
needed to induce cardioplegic arrest (Lawton et al. 1996) are likely to cause lingering 
hypotensive and dysrhythmic effects in patients after weaning from cardiopulmonary 
bypass. 
Adenosine, another clinically-useful compound, has been shown to act as a 
hyperpolarising agent in rabbit SA node cells, with concentrations of ~50 µM inducing 
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a hyperpolarisation of 12-15 mV and arrest of spontaneous beating in myocytes isolated 
from the rabbit’s SA node (Belardinelli et al. 1988). In bovine and guinea pig isolated 
ventricular myocytes, adenosine had no direct effect on contraction, resting potentials or 
action potentials. However, it demonstrated an antagonist effect on the prolongation of 
the action potential caused by the influx of calcium by isoproterenol and almost 
inhibited it completely. It also inhibited the positive inotropic effect of isoproterenol 
(Belardinelli and Isenberg 1983). The binding of adenosine to A1 purinergic receptors is 
coupled to the opening of the acetylcholine (Ach)-activated K
+
-channel (KAch), and it 
can also activate the KATP-channel with the associated additional cardioprotective 
effects (Kirsch et al. 1990). Adenosine (0.2-10 mM) has been used to induce arrest in 
isolated hearts with varying effects on recovery of function; a high dose of (10mM) 
adenosine alone offered a superior cardioplegic hypothermic arrest (10
o
C) over 
hyperkalaemia only or adenosine + hyperkalaemia combined in the isolated rat heart 
with improved recovery and conservation of tissue creatine phosphate (Schubert et al. 
1989). Meanwhile, Jayawant demonstrated that up to 0.2 mM adenosine in an invivo 
rabbit heart has slightly reduced functional recovery following normothermic ischaemia 
compared with pinacidil (Jayawant and Damiano 1998). The main problem with the use 
of adenosine at this low concentration is, again, the prolonged time to achieve electrical 
and mechanical arrest of around 20 min and 7 min respectively, which suggests that the 
mode of arrest was probably ischaemia rather than chemical. 
As an additive to hyperkalaemic cardioplegia, adenosine (0.5-2.0 mM) was shown to be 
beneficial in cardiac surgery patients (Mentzer et al. 1999). Recently, Dobson and 
coworkers showed that a cardioplegic solution utilising a combination of adenosine (0.2 
mM) and lidocaine (0.5 mM) offered significantly improved protection over STH in 
isolated working rat hearts (Dobson and Jones 2004) and had similar protection to STH 
in an in-vivo dog heart preparation (Corvera et al. 2005). Similarly, adenosine (1.2 mM) 
combined with procaine (1 mM) also showed superior protection over hyperkalaemia in 
an in-vivo pig heart model (Jakobsen et al. 2007).  
Although the use of adenosine as the sole arresting agent might not be practical due to 
its extremely short half-life in blood (50-90 sec) (Blardi et al. 1993), it could still 
provide additive benefit to other arresting agents if added to blood-free solutions. 
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1.7.2 Inhibiting Ca2+ activation of the myofilaments  
1.7.2.1 Hypocalcaemia 




-depleted solution developed 
in the early 1960’s, was one of the first solutions to be routinely used clinically 
(Bretschneider 1964). Later, this solution was slightly modified and Ketoglutarate, 
Histidine HCl and Tryptophan were added to formulate the Bretschneider-HTK solution 
(Custodiol
®
), which is still successfully used today. A Ca
2+
-free extracellular media 
prevents Ca
2+
 influx through the L-type Ca
2+
-channels during the plateau phase or phase 




 release from the 
SR, so abolishing the intracellular Catr and preventing activation of the myofilaments 
(Bers 2002). However, Ca
2+
-free solutions, although effective at inducing arrest, are 
limited by the “calcium paradox”, in which massive Ca2+ overloading of the cell occurs 
during reperfusion with a Ca
2+
-containing solution; this is caused by Na
+
, loaded into 
the myocyte during the Ca
2+
-free period, being replaced by Ca
2+





exchanger when the solution with normal extracellular Ca
2+
 levels is reintroduced 
(Chapman and Tunstall 1987). The calcium paradox is avoided, however, by the 
reduction of the extracellular Na
+
 concentration. Bretschneider cardioplegia has been 
shown to be suboptimal during normothermic ischaemia, in contrast to STH, which is 
protective both in hypothermia and normothermia (Jynge et al. 1978). In addition, the 
large infusion volumes of Bretschneider solution (which are needed to remove all the 
extracellular Ca
2+
) require prolonged infusion times making it unwieldy to use from a 
clinical perspective. 
1.7.2.2 Ca2+-channel blockade 
Blocking the calcium channels decreases Ca
2+





release from the SR. Theoretically, this is an effective concept to induce arrest in 
diastole during phase 2 of the action potential (Figure  1.4). Vouhe and colleagues 
(Vouhe et al. 1980) studied the effect of diltiazem compared with high K
+
 in the in-vivo 
dog’s heart and demonstrated better recovery post ischaemia. These myocardial 
protective characteristics were also tested by the use of calcium channel blockers as an 
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additive to hyperkalaemic cardioplegia; Yaliniz and colleagues (Yaliniz et al. 2004) 
demonstrated that small quantities of diltiazem (~1 µM) added to the first and the last 
infusion of tepid potassium cardioplegia in patients who underwent CABG surgery 
resulted in slow SA node recovery in the diltiazem group without any major 
haemodynamic problems. The diltiazem treated group also had less CK-MB rise, which 
confirms the protective effects of diltiazem. However, the prolonged plasma half-life of 
current agents (e.g. 2 hours for verapamil (Popovic et al. 2006) and 5.7 hours for 
diltiazem (Caille et al. 1991)) leads to a long-lasting negative inotropic effect after 
weaning from cardiopulmonary bypass, which is due to the high affinity of these agents 
for the L-type Ca
2+
-channels (Dillon and Nayler 1987). This makes these agents 
unsuitable to be used as arresting agents due to the slow reversibility.  
The ICa,L channels can also be blocked by elevated extracellular Mg
2+
 concentration 
(Iseri and French 1984), despite being less effective than hyperkalaemia at inducing 
arrest (Shattock et al. 1987). Hearse and colleagues (Hearse et al. 1978) demonstrated 
that the addition of elevated Mg
2+
 (16mM) to hyperkalaemic cardioplegia significantly 
improved recovery (see  1.7.1.1 above; elevated Mg
2+
 is a basic component of STH 
cardioplegia. More recently, another study from our lab (Maruyama and Chambers 
2008) investigated the value of using high Mg
2+
 as the arresting agent in a novel non-




RS-I) for a cardioplegic solution. It was 
studied in Langendorff perfused rat hearts in comparison with STH2 cardioplegia. 
Concentration-response study demonstrated that optimal Mg
2+
concentration was 25 
mM, the Mg
2+
 arrested hearts also developed a delayed and less profound ischaemic 
contracture compared with STH2. As for the left ventricular developed pressure 
(LVDP) recovery, the data suggest that Aqix+Mg
2+
 cardioplegia could offer superior 
recovery if used frequently (20 minutes) in normothermic ischaemia  
Due to the easy reversibility of Mg
2+
, hypermagnesaemia is probably the most clinically 
relevant calcium channel blocking agent for use in cardioplegia. 
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1.7.2.3 Influencing the sensitivity of myofilaments to Ca2+ 
2,3-butanedione monoxime (BDM), originally developed as an antidote to sarin 
poisoning, was found to arrest cardiac myocytes without altering the calcium transient. 
Vahl and colleagues (Vahl et al. 1995) demonstrated in the human ventricular muscle 
strips loaded with the calcium dye, Fura-2, that 30 mM of BDM completely inhibited 
the force generated by contraction with only partial reduction in the calcium transient. 
BDM induces inhibition of force-producing cross-bridge formation within the 
myofibrils (Gwathmey et al. 1991) despite the rise in intracellular calcium levels during 
the action potential. Snabitis and colleagues (Snabaitis and Chambers 1999) studied the 
effect of BDM as an additive to a “polarising” solution using TTX as the arresting agent 
during long term preservation storage studies (8 hours of ischaemia) in working mode 
rat heart preparations. They demonstrated that BDM (30 mM) increased aortic flow 
recovery from 56% to 76% of control when added to a preservation solution 




 exchanger inhibitor 






 co-transporter inhibitor furosemide. This offered 
significantly improved preservation compared with STH2 solution with recovery of 
26%. Jayawant and colleagues (Jayawant et al. 1999) studied the concept of 
cardioplegic arrest using BDM as an arresting agent rather than as an additive in rabbit 
perfused hearts undergoing ischaemia with multiple infusions of blood-based 
cardioplegia. BDM (20 mM) offered LVDP recovery comparable to STH2 cardioplegia. 
The BDM group, however, had much shorter atrio-ventricular (A/V) interval with lower 
chance of complete heart block compared with the control and STH groups. 
Like many other arresting agents mentioned earlier, despite the experimental evidence 
of the advantages offered by BDM, the use of it in myocardial protection was never 
translated to the clinical arena. A possible explanation for this might be that BDM 
concentrations required to induce complete arrest or offer any protection are very high 
(20-30 mM), with a potentially strong calcium chelating effect that may make it too 
toxic. In summary, in vitro evidence suggests an advantage in using BDM as an additive 
to high K
+
 cardioplegia for better myocardial protection in the rat (Snabaitis and 
Chambers 1999). What is not very clear is how safe are these protective doses of BDM 
and how wide is the benefit safety margin. 
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1.8 Alternative methods of myocardial protection during surgery 
Surgeons had to operate on the beating heart prior to the development of 
cardiopulmonary bypass and the first operation performed for coronary artery disease 
was on a beating heart in 1936 (Marvin 1941). The introduction of cardiopulmonary 
bypass (CPB), however, ensured cardiac surgery became a great success due to the ease 
and the predictability of operating on an arrested heart by hyperkalaemic cardioplegia 
and CPB-supported circulation (Pfister et al. 1992). Interestingly, in 1972, and hardly a 
decade passed with the comfort of operating on an arrested heart, Ankeney reported his 
experience of performing CABG on beating hearts without the support of 
cardiopulmonary bypass to The Society of Thoracic Surgeons in the USA (Pfister et al. 
1992). This has started a very wide trend worldwide to perform coronary surgery on 
beating heart and becomes a well established technique called off pump surgery. Off 
pump surgery is beyond the scope of our work, which mainly investigates strategies for 
myocardial protection against global ischaemia during cardiopulmonary bypass. 
However, the modern experience of off pump surgery along with the culture of 
exploring alternative strategies to improve outcome resulted in the following alternative 
methods to conventional cardioplegic arrest.  
1.8.1 Intermittent cross-clamp fibrillation 
Intermittent cross clamp fibrillation (ICCF) is a well established method of 
cardioprotection during coronary artery bypass (CABG) surgery, which offers a 
relatively quiescent and bloodless surgical field during CABG. This technique involves 
exposing the heart to intermittent short episodes of global ischaemia (around 10 min 
each) while the surgeon is constructing the distal coronary anastomosis of each graft. 
The heart is maintained in ventricular fibrillation (VF) during this period, with the heart 
being fully reperfused and defibrillated at the end of each CFF. In 2004, a UK survey 
(Karthik et al. 2004) showed that 17% of surgeons continued to use this strategy in 
coronary surgery as their predominant method of myocardial protection during CABG. 
The advantage of this technique is to minimise the length of ischaemia to 10 to 15 
minutes at a time and establish reperfusion as soon as possible, as it is thought that the 
myocardium can tolerate this levels of ischaemia without sustaining irreversible injury. 
CHAPTER 1: INTRODUCTION 
57 
Additionally, intermittent cross-clamping would mimic ischaemic preconditioning by 
exposing the myocardium to short periods of ischaemia (Abd-Elfattah et al. 1995; Fujii 
and Chambers 2005) and makes the heart more tolerant to subsequent periods of 
ischaemia while performing the subsequent grafts. Numerous studies were conducted in 
order to determine the effectiveness of this method over cardioplegic arrest and showed 
comparable results despite common belief that cross-clamp fibrillation results in higher 
cardiac enzyme release and embolic events due to the constant handling of the aorta 
(Scarci et al. 2009) and the concern of inadequate perfusion between the consecutive 
episodes of ischaemia (Dunning et al. 2006). There is no evidence relating to the trend 
for using cross-clamp fibrillation since 2004; however, as patients becoming sicker with 
more diffused disease being operated on with multiple vascular targets, it is likely that 
this method for myocardial protection is in decline. We analysed retrospective data from 
STH, and showed that in patients with EuroSCORE (European System for Cardiac 
Operative Risk Evaluation) more than 9, ICCF gave better long term survival than 
cardioplegia (Scarci 2010). This study has its limitation as it looked at the mortality 
rates retrospectively without taking into account the cause of death in both groups. 
Therefore the endpoint of this study might not be reflecting the best myocardial 
protection strategy in these two groups. Equally, a study by Dunning and colleagues 
demonstrated that the reperfusion between the episodes of cross clamps in this method 
of protection can be variable and unreliable (Dunning et al. 2006). 
1.8.2 Systemic hypothermia and a non-ischaemic elective fibrillatory arrest 
This technique is rarely used; it is performed without cross-clamping the aorta or 
exposing the heart to ischaemia. Systemic hypothermia (28°C) is achieved with 
cardiopulmonary bypass and elective fibrillatory arrest is induced with maintenance of 
systemic perfusion pressure at between 80 and 100 mm Hg; allowing certain procedures 
like redo surgery with patent grafts from previous CABG to be performed safely; In 
1984, Akins and colleagues (Akins 1984) reported
 
a low incidence of perioperative 
infarction and a low hospital mortality
 
rate in 500 consecutive patients using this 
technique. The limitations of this technique include the bloody
 
surgical field during 
surgery without cross-clamping the aorta, which therefore limits its use to CABG and 
sometimes mitral surgery. Less importantly ventricular fibrillation is associated with 
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increased muscular
 tone, which can limit the surgeon’s ability to position the heart for 
optimal exposure. It is generally not
 
applicable for intracardiac procedures (Okamura et 
al. 1996);
 
however, certain modifications can be adopted in order to overcome these 
limitations and perform intra-cardiac procedures like mitral valve surgery adopted when 
it is difficult to induce ischaemia in redo surgery with patent coronary grafts. In these 
situations, cross-clamping can be applied to offer a relatively bloodless field or 
alternatively, low systemic perfusion pressures with further cooling (Byrne et al. 1999). 
1.8.3 Minimal myocardial contraction 
This strategy was first explored clinically in the early nineties by Sweeney and Frazier 
in patients with very poor ventricles by supporting circulation with partial bypass using 
ventricular assist devices and inhibition of contraction using high doses of the short-
acting β-blocker esmolol (Sweeney and Frazier 1992). This ensured avoidance of 
ischemia by continuous perfusion in this sick group of patients with a relatively flaccid 
and slow heart by using esmolol, which assists the surgeon to construct good quality 
anastomosis. The introduction of esmolol by Sweeney and colleagues was through a 
unique strategy, which offers middle ground between off-pump and on-pump surgery 
and resulted in a very good outcome to patients with poor prognosis due to their very 
poor ventricular function. Kuhn-Regnier (Kuhn-Regnier et al. 1999) and colleagues 
have adopted this concept of reducing contraction using systemic esmolol effusion and 
applied it to coronary artery surgery with CPB, aortic cross-clamp and direct continuous 
coronary perfusion with esmolol enriched blood. This method offered the advantage of 
avoiding ischaemia while operating on an empty heart that was relatively easy to 
manipulate. It was also used for performing intra-cardiac surgery by Scorcin and 
colleagues (Scorsin et al. 2003) and who used the term minimal ventricular contraction. 
The use of esmolol in cardiac surgery was not limited to minimal ventricular 
contraction; it was used as an adjunct to conventional cardioplegia by us (Fujii et al. 
2006) and others (Booth et al. 2002; Boldt et al. 2004). It was also used in off-pump 
surgery (Arlock et al. 2005) and as an alternative to conventional cardioplegia 
experimentally in our lab (Bessho and Chambers 2001; Bessho and Chambers 2002) 
and by others (Geissler et al. 2000).  
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The short-acting β-blocker, esmolol, was used in various settings in cardiac surgery 
aside minimal ventricular contraction; the following section will shed some light on the 
development of β-blockers and explore the benefit of esmolol in cardiac surgery. 
1.9 β-blockers and esmolol 
The β-receptors are part of the sympathetic nervous system which respond to 
catecholamine (adrenaline and noradrenaline) (Ahlquist 1948). The β-receptors relevant 
to the heart are β1 receptors and they are activated by coupling with Gs protein which 
increases cAMP resulting in increase contraction tachycardia (Drake 2005). The 
development of the first β-blocker propranolol in 1962 (Black and Stephenson 1962) 
has revolutionised the treatment of ischaemic heart disease, hypertension and 
arrhythmia (Harrison et al. 1965; Waal 1966; Mason et al. 1969). However, propranolol 
was a non-selective β blocker which was responsible for its non cardiac side effect. This 
has resulted in developing more cardiac selective β-blockers targeting the β1 cardiac 
receptors which led the development of a group of β-blockers like atenolol, bisoprolol 
and metoprolol. These agents remained the cornerstone in the treatment of ischaemic 
heart disease, arrhythmia and hypertension until today (Cruickshank 2000). More 
recently agents like carvedilol, which are less selective to β1 receptors have 
demonstrated increased benefit in the treatment of heart failure due its additional alpha 
blocking activity (Packer et al. 1996). Interestingly, recent evidence suggests that the 
variation of selectivity among different β-blockers is not as profound as it was thought 
to be (Owens 2005).  
In order to extend the benefit of β-blockers beyond its chronic use in angina and chronic 
hypertension, the development of an ultra-short acting β1 selective blocker esmolol has 
led to expanding its use to treating other conditions like acute hypertension in critical 
care and cardiac surgery as explained earlier. As esmolol is main scope of this work the 
following section looks at esmolol in details.  
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Figure  1.12  Esmolol molecular formula with the ester link (squared) compared with 
atenolol which is responsible for the fast metabolisation in the red cells
Esmolol (ASL-8052), an ultra-short acting  cardioselective beta-blocker, was first 
developed by Edhart and colleagues (Erhardt et al. 1983) in 1983 and is a phenoxy-
propranolamine with a half-life in-vivo of 9 minutes. The molecule  has an ester link in 
the para-position of the phenyl ring ( Figure  1.12) that is responsible for the esmolol 
cardioselectivity and ultra-short duration of action of the drug (Zaroslinski et al. 1982).
It is registered in the UK for the treatment of supraventricular tachycardia, post-
operative hypertension (Gray et al. 1985) and tachycardia syndrome according to 
the British National Formulary (BNF). Roth and colleagues studied the effect 
of esmolol on reperfusion injury in regional ischaemia in 
an in-vivo canine heart preparation using LAD artery ligation and demonstrated that the 
infusion of esmolol at reperfusion decreased free radical mediated injury (Roth and 
Torok 1991) and inhibited the inflammatory response (Roth et al. 1995). The anti-
ischaemic properties of esmolol were examined clinically in patients with unstable 
angina by Hohnloser and colleagues (Hohnloser et al. 1991); esmolol was administered 
in patients with diagnosed unstable angina and was titrated against blood pressure (BP) 
and heart rate. Compared with the placebo group, there was significant reduction in the 
need to proceed to urgent revascularisation and lower tendency to develop silent angina 
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The bradycardic effect of esmolol, as well as the mounting evidence on its protective 
effects against ischaemia, encouraged many groups to explore its value in cardiac 
surgery. It was used by Booth and colleagues (Booth et al. 2002) to assess any 
protective effect of systemic infusion of esmolol during CPB and cold hyperkalaemic 
cardioplegia in a canine preparation with prior LAD occlusion on post ischaemic 
function, to mimic CABG patients. The β-adrenergic receptor density in biopsies taken 
from the ventricles was comparable in both the esmolol and placebo groups; however, 
isoproterenol-stimulated adenylyl cyclase activity was significantly improved post-
bypass in the esmolol group. This can explain the improved systolic contraction post-
CPB, possibly by better inotropic response to catecholamine. Clinically, Boldt and 
colleagues (Boldt et al. 2004) studied esmolol in combination with the 
phosphodiesterase III inhibitor, enoximone, as a supportive drug for its myocardial 
protective specifications against global ischaemia. The combination was administered in 
the perioperative period as a systemic infusion in patients over the age of 65 undergoing 
CABG. Compared with placebo, the treatment group had a better myocardial protection 
profile, and presented with higher cardiac index and less troponin and CK rise post 
operatively. There was also less rising in the plasma inflammatory markers interleukins 
6 and 8 levels and in polymorphonuclear elastase levels in the treatment group. 
Meanwhile work from our lab (Fujii et al. 2006) examined the use of esmolol as an 
additive to blood potassium cardioplegia in the isolated rat hearts and showed no added 
protection.  
In a different application, esmolol was used as an alternative to cardioplegia rather than 
as an adjunctive measure of myocardial protection. The concept of minimal ventricular 
activity by esmolol explained earlier was examined experimentally by Geissler and 
colleagues (Geissler et al. 2000). They used an in-vivo canine cardiopulmonary bypass 
(CPB) similar to the model described earlier by Booth and colleagues (Booth et al. 
2002) to mimic emergency CABG. After establishing CPB, the dogs were randomised 
into two groups; one received warm blood cardioplegia and the other warm blood with 
high doses of esmolol in the aortic root. Myocardial water content as well as global and 
regional LV function were measured post-CPB. There was comparable LV function in 
both groups; meanwhile, the esmolol group demonstrated lower water contents and less 
oedema. Clinically, the same concept of minimal ventricular activity by esmolol was 
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compared with high potassium blood cardioplegic arrest by Kuhn-Regnier and 
colleagues (Kuhn-Regnier et al. 1999) in a randomised controlled trial of 60 low-risk 
patients undergoing CABG. There was comparable outcome in both groups in terms of 
post-operative complications, inotropic support, enzyme release and ICU length of stay. 
However, there was significant improvements in cardiac index measurements in the 
esmolol group 4 hours post-operatively. Similarly, in the esmolol group there was a 
significantly decreased lactate release in the coronary sinus during CPB. The same 
group reported their experience in using esmolol in the same manner in 200 high risk 
patients with average EuroSCORE of 6 undergoing CABG operation (Kuhn-Regnier et 
al. 2002). They demonstrated morbidity and a mortality rates within the expected range 
as per EuroSCORE. The authors then concluded that esmolol continuous warm infusion 
into the coronary arteries is a safe and effective technique in CABG procedures; it may 
be especially advantageous in high-risk patients.  
The use of esmolol as an alternative to cardioplegia explained thus far has been to 
maintain continuous perfusion minimal ventricular contraction with no ischaemia or 
arrest. This was shown to be a useful mean of performing cardiac surgery however it 
does not offer the advantage of a bloodless and quiescent surgical field offered by 
conventional cardioplegia (see Section  1.6.1). Work from our lab (Bessho and 
Chambers 2001) has shown that high concentrations of esmolol (~1.0 mM), can induce 
cardiac arrest in the Langendorff perfused hearts. Esmolol was, therefore, used as a 
conventional arresting cardioplegic agent in these experiments rather than minimal 
ventricular activity. The optimal method of esmolol cardioplegia was studied comparing 
intermittent versus continuous administration and flow controlled versus pressure 
controlled coronary perfusion. It was concluded that the use of high doses of esmolol 
was proven to be a safe cardioplegic agent and, when given in an oxygenated perfusate, 
was superior to St. Thomas’ Hospital cardioplegia or cross-clamp fibrillation in terms of 
LVDP recovery after prolonged periods of ischaemia (Bessho and Chambers 2001; 
Bessho and Chambers 2002). However, the mechanism of cardiac arrest induced by 
esmolol in these studies is not clear and could not be entirely explained by its β-
blocking effect, especially in a Langendorff heart preparation the existence of a 
catecholamine background release is not very clear; Adrenaline for instance is 
catecholamine with β receptor agonism properties and therefore will be responsible for 
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any sympathetic effect on the heart. Potentially, it can be released from the nerve 
endings which would have been divided during harvesting the heart. These sympathetic 
nerve endings are formed by the axons of the postganglionic sympathetic neurones 
placed in the thoracolumbar sympathetic chain of the spine (Drake 2005), any possible 
adrenaline activity in this model is not likely to be prominent after the stabilisation 
period of the experiment. In these experiments esmolol had a negative inotropic effect at 
high concentrations, which resulted in 25% decrease in LVDP at 0.1 mM without 
significant effect on heart rate. This negative inotropic effect progressed to a complete 
ventricular arrest at 1 mM with ongoing atrial activity (Figure  1.13). These findings 
suggest that esmolol-induced arrest could be caused by the failure of contraction due to 
the profound negative inotropic effect. It is also possible that dissociation between atrial 
and ventricular activity at 1 mM could be due to either complete heart block at the level 
of the AV node or the downstream conduction system, which again can explain the 
arrest by esmolol (at 1 mM). Alternatively, this might be simply due to poor atrial 
perfusion in this preparation, which reduced esmolol bioavailability so it failed to 
inhibit contraction in the atria. All these possible mechanisms can explain the arrest by 
esmolol (1 mM) but none suggests any involvement of the β-receptors in hearts isolated 
from any catecholamine background. One possible effect of esmolol in such preparation 
on β-receptors is by acting as an inverse-agonist and activating PKA-dependent 
mechanisms (Baker et al. 2003). However, this effect would be expected to induce 
positive inotropic effect and to not require such high concentrations. Therefore, there 
must be another mechanism by, which high dose esmolol is able to induce cardiac arrest 
independent from its β-blocking effect. 
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Figure  1.13 Log dose response curves of LVDP (open squares), ventricular rate 
(closed diamonds), and atrial rate (open circles), with increasing concentrations of 
esmolol in KHB as percentage of the baseline value. (from Bessho and colleagues 
(Bessho and Chambers 2001)) 
In order to establish the mechanism of esmolol arrest or even its negative ventricular 
inotropic effect in the isolated heart, we conducted some pilot studies in isolated rat 
cardiac myocytes. The isolated rat ventricular myocyte loaded with the Ca
2+
 sensitive 
dye, Indo-1 and were electrically-stimulated. The myocyte contraction was studied in an 
edge-detection and the Ca
2+
 transient was measured using fluorescence microscopy 
(Figure  1.14). Esmolol (at 1 mM) inhibited myocyte shortening completely (i.e. induced 
arrest); however, atenolol (at 1 mM) had no effect on myocyte shortening. Infusion of 
esmolol (1mM) on an atenolol (when the β-receptors should be blocked) still induced 
complete inhibition of myocyte shortening. Despite arresting the myocyte, esmolol did 
not abolish the Ca
2+
 transient although there was a decline of around 40%, suggesting 
that esmolol could have a desensitising effect on the myofilaments to calcium. 
Additionally, this suppressive effect on the Ca
2+
 transient could be either by blocking 
(mM) 




 entry into the cell via the voltage dependent L-type Ca
2+











Figure  1.14 Isolated rat ventricular myocyte electrically stimulated with cell length 
measured using cell edge detection and Ca transient measured using Indo-1 (pilot 
data performed by A James and colleagues) 
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1.10 Hypothesis and Aims  
These different mechanisms mentioned above, which can explain the arresting mode of 
action of esmolol suggest the following hypotheses: 
1. Esmolol has a negative inotropic effect and induces cardiac arrest through 
mechanism(s) independent from its β-adrenoceptor blocking effect. 
2. The decreased Ca2+ transient (panel B, Figure  1.14) suggests that esmolol might 
influence the L-type calcium channels or act directly on the SR at intracellular 
level. 
3. The abolition of myocyte shortening and the reduced calcium transient (panel B 
of Figure  1.14) suggests a possible direct desensitising effect of esmolol on the 
myofilaments to calcium. 
4. The atrio-ventricular dissociation induced by esmolol at (Figure  1.13) suggests 
possible effects on the conduction system of the heart. 
5. The use of esmolol as an arresting agent could offer a new mechanism for 
induction of cardioplegic arrest that is superior to hyperkalaemic arrest.  
The aims of our studies to address these hypotheses are: 
1. To study the effect of esmolol on contraction and the calcium transient in 
isolated myocytes. 
2. To study the effect of esmolol on the myofilaments sensitivity to calcium in 
isolated skinned myocytes. 
3. To study the effect of esmolol on the L-type calcium channel and the 
sarcoplasmic reticulum (SR). 
4. To study the arresting effect of esmolol on the conduction system in 
Langendorff perfused hearts. 
5. To investigate the effects of esmolol as a cardioplegic agent on whole heart 
preparation as a basis for developing an alternative cardioplegic solution to 
hyperkalaemia. 
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1.11 Key Characteristics of the difference between the rat heart and 
the human heart 
 
The rat heart has always been a good way to conduct cardiac research and major 
discoveries have been made from working on the rat heart like the use of ACEI 
following MI (Pfeffer et al. 1985; Pfeffer et al. 1985), the use of endothelin receptor 
agonist in the treatment of pulmonary hypertension (Sakai et al. 1996) and many more 
examples. However, there are important anatomical and physiological differences 
between the rat hearts and the human hearts beyond the difference in size, which should 
be considered during any experimental work and are explained here:  
1.11.1 Anatomical variations 
The issue with size difference is very important issue in our studies as the small 
coronary arteries of the rat hearts could potentially make the application of any coronary 
treatment dependent on the viscosity of this preparation in the rat more than that in the 
human. This was noted in studies we conducted using esmolol and blood cardioplegia 
which resulted in slower coronary perfusion in the rat heart compared to crystalloid 
preparations (Fujii et al. 2006).  
Other anatomical variations are also important; for instance the coronary artery do not 
lie on the surface of the myocardium like the human hearts, instead they have an intra-
myocardial course (Halpern 1957). The septum is usually largly supplied by the right 
coronary artery with the largest septal branches arising from the origin of the RCA. The 
circumflex artery is ill defined in the rats as well. More importantly the blood supply to 
the heart is not limited by the coronary artery but also gets some supply from extra-
cardiac branches like the cardiacmediastinal arteries which gives rises to the internal 
mammary arteries (Halpern 1957).  
Another important variation is the presence of a left and right superior vena cava (SVC) 
instead of an innominate vein in the rats. The right SVC drains in the usual site on the 
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right atrium while the left drains into the coronary sinus. We have been fully mindful of 
these variations in designing out experimental protocols  
1.11.2 Electrophysiological variations 
The SA node in the rat is situated at the junction of the right SVC and the right atrium. 
However, the blood supply to the SA nodes originates from the extra cardiac branches 
explained above (Halpern 1957). The heart rate of the rat is significantly faster than 
human heart which makes the assessing the ECG for ischaemic changes difficult. 
Otherwise, morphological studies examining the intracardiac nerve plexus in the rat 
hearts using acetylcholenesterase histochemistry methodology demonstrated that the 
intrinsic nerve supply fits within the same anatomical scheme as the human nerve 
plexus. This suggests that the rat model offers a suitable alternative to investigate the 
effect of the intrinsic nerve supply on the heart (Batulevicius et al. 2004). This is 
particularly relevant to investigate cardioplegic arrest in the heart. In summary, it seems 
that the mammal’s hearts in general has a common micro and macro anatomical 
structure in the conduction apparatus and any adaptation was achieved in the function of 
the heart (Meijler 1985) 
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CHAPTER 2. METHODOLOGY 
2.1 Animals 
In the studies described in this thesis, adult males Wistar rats weighing 240 and 325 g 
were used. All animals received humane care in accordance with the “Guidance on the 
Operation of the Animals (Scientific Procedures) Act of 1986” (HMSO, London, 
England) 
2.2 Solutions and reagents  
Reagents and enzymes were supplied by Sigma-Aldrich Chemicals Ltd. (MO), unless 
otherwise stated. All solutions were made with ultra-pure water (resistance >16 M). 
2.2.1 Tyrode solution for intact isolated myocytes studies 
This was prepared by adding the following ingredient (in grams) to 900 ml ultrapure 
water; NaCl, 8.19; KCl, 0.40; Na2HPO4, 0.14; MgSO4.7H2O, 0.25; HEPES, 1.19; 
Glucose, 1.8; then 1 ml of 1M concentration stock solution of CaCl2 was added to the 
mixture. More pure water was added to make the total solution volume to a litre after 
ensuring all the salts are dissolved. The final concentrations in the solution are (mM): 
NaCl, 140; KCl, 5.4; Na2HPO4, 1; MgSO4.7H2O, 1; HEPES, 5; glucose, 10 and CaCl2, 
1. Then pH was adjusted to 7.45 at the temperature of the experiment with 1M stock 
NaOH. For the calcium transient measurement, the fluorescent calcium indicator fura-2 
AM (Calbiochem) was used as a 2 mM stock solution dissolved in dimethylsulphoxide 
(DMSO). For the SR blocking studies, the cells were treated with thapsigargin (2 µM) 
for 20 minutes in a Tyrode solution containing 7 mM CaCl2 instead of 1 mM (for 
further details see Chapter 5). 
2.2.2 Solutions for skinned myocytes 
For the skinned myocytes experiments, the solutions were prepared and kept in plastic 
containers to prevent any contamination with calcium from glassware. Furthermore, 
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stock solutions of 500 mM N-bis[2 hydroxyethyl]-2-aminoethanesulfonic acid (BES) 
and 1M Potassium propionate (KPr) were prepared, pH neutralised with 1M KOH, and 
passed through a chelex-100 column (Bio-rad, CA). Chelex was supplied in the Na
+
 
form. The chelex beads were changed, initially to the H
+
 form by washing in 1 M HCl, 
and then to the K
+
 form using previously-chelexed KOH. During treatment of the 
solution with chelex, the contaminant Ca
2+
 was removed and K
+
 was released into the 




-free relaxing solution (Kentish 1986) contained (in mM): KPr, 70; BES, 100; 
disodium creatine phosphate (Na2CP), 10; Na2H2ATP, 6.3; Mg
2+
ATP, 5; K2EGTA, 10; 
The purity of EGTA was assumed to be 96.3% (Kentish 1986). Na2H2ATP and Na2CP 
were added as solids. The pH was adjusted to 7.1 at 23°C with 1M chelexed KOH and 
ionic strength was 200 mM. DTT (1 mM) was added on the day of experiments. To 
prevent degradation of protein, protease inhibitors (Complete Mini protease inhibitor 
cocktail tablets) were added to relaxing solution (1 tablet per 10 ml) according to the 
manufacturer’s instructions (Roche Diagnostics, I.N). These inhibit serine proteases, 
cysteine proteases and metalloproteases. The skinning solution was relaxing solution 
with 1% Triton X-100 v/v. Storage solution was a mixture of relaxing solution and 
glycerol (50:50 v/v). 
Maximal activating solution was prepared as per relaxing solution but with replacement 
of K2EGTA with 10 mM CaK2EGTA. A CaK2EGTA stock solution (50 mM) was 
prepared by heating solid CaCO3 and solid EGTA to 80°C, which combined together to 





-activating solutions were prepared by appropriate combinations of 
50 mM K2EGTA and 50 mM CaK2EGTA to give a full range of total Ca
2+
 
concentrations from zero to 50 mM, corresponding to a range of 0–10 mM in the final 
solutions. The range of Ca
2+
-activating solutions, together with the final Ca
2+
 
concentrations and calculated pCa values, are shown in Table  2.1.  
As a result of the temperature-dependent pKa of BES, at lower temperatures solutions 
become more alkaline, with a 0.016 pH unit change for each 1°C decline in temperature. 
Therefore, for experiments conducted at 15°C, the pH was set to 6.94 at RT (23°C) 
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Table  2.1 Ca
2+
 solution calculations for the skinned myocyte activating solution 
 
2.2.3 Solutions for ICa,L  patch clamping 
Pipette solutions were prepared by adding the following ingredients in 90 mls of ultra-
pure water (mM): L-aspartic acid, 1.13; CsOH, 1.43; TEA Cl (tetraethylammonium 
chloride), 0.33; HEPES, 0.24; EGTA, 0.038; MgATP, 0.2; Na-GTP, 0.005; NaCP,0.16. 
MgCl2 was prepared as 1 M stock and 0.1 ml. was added. Then the pH was adjusted to 
7.2 using CsOH. Ultra pure water was then added to make the solution’s volume to 100 
mls. The solution was filtered using 0.5 micron cellulose fibre filters. The final 
Total [Ca
2+





5.5 0.34 6.47 
6 0.42 6.38 
6.5 0.51 6.29 
7 0.65 6.19 
7.5 0.83 6.08 
8 1.10 5.96 
8.5 1.55 5.81 
9 2.45 5.61 
9.5 5.13 5.29 
10 31.62 4.5 
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concentrations were; L-aspartic acid, 85; CsOH, 85; TEA Cl (tetraethylammonium 
chloride), 20; HEPES, 10; EGTA, 1; MgCL2, 1; MgATP, 4; Na-GTP, 0.1; NaCP,5. 
The external solution was the Tyrode solution mentioned above for the isolated myocyte 
studies (Section  2.2.1) 
2.2.4 Solution for INa patch clamping 
The pipette solution was prepared as mentioned above in the ICa,L patch clamping 
solutions. The final solution contained (mM): NaCl, 5; CsCl, 20; Cs-methanesulfonate, 
110; MgCl2, 1; Mg2ATP, 5; HEPES, 5; EGTA, 5; pH 7.2 with CsOH  
External solution (mM): NaCl, 5; CsCl, 135; MgCl2, 1; glucose 10; CaCl2, 0.5; CoCl2, 
0.5; HEPES, 5; pH 7.4 with CsOH. 
A summary of the internal and the external solutions contents is presented later on in 
Figure  2.8. 
2.2.5 Esmolol (Brevibloc® , Baxter) 
Esmolol (Brevibloc®) was stored as the concentrated preparation for intravenous 
infusion at a concentration of 250 mg/ml (755 mM), and was added at the desired 
concentrations to the Tyrode solution in isolated myocyte experiments, to the external 
solution in patch clamping experiments and to KHB in the Langendorff perfused heart 
studies. 
2.2.6 Atenolol 
Atenolol (Sigma Chemicals) was diluted in the Tyrode solution mentioned above at 1 
mM concentration.  
2.2.7 Solutions for the isolated Langendorff perfused rat hearts 
Krebs Henseleit Buffer (KHB) solution was used in the Langendorff perfused rat hearts 
experiments and contained (mM: NaCl, 118.5; NaHCO3, 25.0; KCl, 4.75; MgSO4, 1.2; 
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CaCl2, 1.4; and glucose, 11.0), filtered (5 μm pore size) and gassed (95% O2/5% CO2, 
giving a pH of 7.4 at 37°C).  
2.2.8 St. Thomas’ Hospital Solution No.2 (STH) 
STH was used in the Langendorff perfused rat hearts experiments and contained (mM: 
NaCl, 110; NaHCO3, 10; KCl, 16; MgCl2, 16 and CaCl2, 1.2), filtered (5 μm pore size). 
 
2.2.9 Lidocaine 
Lidocaine (by Nova, UK) local anaesthetic (2%) solution was used as stock solution and 
was added to KHB solution at the desired concentrations in the Langendorff perfused 
rat heart studies. 
2.2.10 Adenosine 
Adenosine (Sigma Chemicals) was diluted in the KHB solution mentioned above at the 
desired concentrations in the Langendorff perfused rat heart studies. 
2.3 Studies using isolated myocytes 
2.3.1 Isolation of ventricular cardiomyocytes 
Isolation of the ventricular myocytes is a technically complex process. We were 
fortunate to have the services of a technician trained in this technique. Adult male 
Wistar rats, weighing 200-250 g were used. Rats were anaesthetised with pentobarbital 
sodium (50 mg/kg) intra-peritoneally. Then, 200 IU of heparin was injected into the 
femoral vein. The chest was then opened through a top-roof incision in the abdomen 
and the heart was exposed and excised. The heart was rapidly mounted on a cannula and 
perfused through the aorta via a Langendorff perfusion system at a controlled pressure 
of 100-110 cm of water. The heart was perfused with HEPES buffered Tyrode solution 
with the following composition (in mM): NaCl, 110; KCl, 5.4; MgCl2, 1.4; NaH2PO4, 
0.4:  HEPES, 4.2; glucose, 10; taurine, 20; creatine, 10 and CaCl2, 1. The pH was 
adjusted with NaOH at 1 M concentration to 7.35 and the solution was perfused at 37
o
C 
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and gassed with 100% O2. After 2 minutes of stabilisation, the heart was perfused with 
calcium-free Tyrode solution (as above but with no CaCl2 and with 0.1 mM EGTA) for 
4 minutes, and subsequently with the Tyrode solution and collagenase type II 
(Worthington Biomedical Corporation) at a concentration of 250 U/ml for 10 minutes. 
The heart was then removed from the Langendorff perfusion system and the ventricles 
were isolated and finely minced using sharp scissors. The divided and minced ventricles 
were then incubated in collagenase solution with bovine serum albumin 1mg/ml for a 
further 5 minutes. The temperature was kept at 37
o
C and the solution was always gassed 
with 100% O2. The solution was filtered (at 200 µm) into a test tube. The undigested 
homogenate was incubated for another 5 minutes with the collagenase solution and 
filtered as before for another two cycles. The myocytes from each cycle were kept 
separately. Subsequently, they were washed and resuspended in a 1 mM CaCl2 solution. 
The cells from each cycle were assessed by the shape (rod shaped), the highest yield and 
the vitality and the best batch was used. The second cycle tended to be the most 
commonly used. Due to the small number of cells required for the experiments in this 
project, the myocyte suspension was usually shared with other colleagues in the 
department to limit the cost and the number of animals used. 
2.3.2 Myocyte permeabilisation 
Isolated rat ventricular myocytes were permeabilised for the skinned myocyte 
experiments by re-suspension in the skinning solution (relaxing solution with 1% Triton 
X-100 v/v) for 15 minutes. Cells were kept on ice during the skinning procedure. The 
cell suspension was then centrifuged for 3 minutes at 350 g, the supernatant removed 
and the myocyte pellet resuspended in relaxing solution at 4
o
C. This cycle of 
centrifugation and resuspension was repeated three times with relaxing solution to 
remove any traces of Triton X-100. The myocyte fragments were then resuspended in 
relaxing solution and used for the calcium sensitivity studies (these experiments were 
performed with the help of Dr. S. Bardswell).  
2.3.3 Apparatus for sarcomere measurement 
The apparatus was located in an air-conditioned room to maintain room temperature 
around 23
o
C. It consisted of an inverted microscope (Nikon) on an air-balanced anti-
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vibration table. The myocyte solution was loaded into a perspex bath with a glass 
coverslip creating a water-tight base using grease. The bath contained two platinum 
electrodes along the chamber to stimulate the cells using an IonOptix stimulator with 
voltage and frequency adjustment capability. The bath was perfused using 8 perfusion 
channels elevated above the bath and connected to a manifold just before the bath to 
allow fast switching between solutions. The perfusion lines were heated through 
temperature-adjusted water jacketing closer to the bath end to eliminate any heat loss. 
The chamber was mounted above a dry non-phase fluorescence x40 objective lens 
(Nikon numerical aperture 0.8) of the inverted microscope. The light filters were used in 
the fluorescence experiment as shown in Figure  2.1.  
 
Figure  2.1 Diagram of apparatus for myocyte sarcomere length and calcium transient 
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The sarcomere length (SL) measurements were studied via a variable field rate video 
camera connected to the computer and displayed on a separate monitor at a rate of 240 
Hz (Figure  2.1). SL measurements were analysed via IonOptix software (Milton, MA, 
USA). The sarcomere (Figure  2.2) is the contractile unit in the myocyte and it is 
bordered by the two Z-lines to, which the thin filaments are attached. With the thick 
myofilaments in the middle it creates alternating dark (A) and light (I) bands, which 
give the striation appearance. The SL is the distance between the two Z-bands to, which 
the filaments are attached, with the thick filament in the middle. The IonOptix system 
uses this striation appearance to calculate the average sarcomere length (SL). IonOptix 
also registers an event signal on the chart every time there is electrical stimulation in the 
bath. 
 
Figure  2.2: Diagram of Sarcomere structure 
The sarcomeres are aligned horizontally on the screen by rotating the camera so the 
striations are aligned vertically. A region of interest (ROI) is then defined (by the 
operator) in the myocyte by positioning the rectangle with dimensions of about 10x10 
µm, which will include around 50 sarcomeres. The larger the ROI, and the more 
sarcomeres it contains, the more accurate are the results. The pattern of contractions 
results in the edges of the myocytes to be drawn to the steady centre; this could lead to 
over-estimating of the sarcomeres away from the centre. Therefore, it is essential to 
select an area near the centre to ensure that only the sarcomere shortening element is 
measured and not the drawing effect of the sarcomere movement. The mean SL in the 
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ROI was calculated using IonOptix software by measuring the sinusoidal light intensity 
of the dark and light bands in the striations across the video scan lines, i.e, sinusoidal 
waves with the period equal to the SL (Figure  2.3). Fast Fourier Transform (FFT) 
analysis calculates the average frequency of the sinusoid. The software calculates the 
average of the FFTs from each video line; alternatively, it obtains fast measurements of 
the sarcomere length by measuring single FFT from the average of all scan lines in the 
ROI. The latter method was chosen as it gives better real time measurements. The 
statistical power of the FFT measurement is calculated by the software and presented as 
a peak curve (Figure  2.3); narrow peak indicates more accurate SL measurement with 
less deviation from the average. This is to exclude poor SL measurements. The 
difference between the SL at maximum shortening (systole) and maximum resting 
relaxation (diastole) was calculated and called the sarcomere shortening (SS) as an 
indication of myocyte contractility in response to electrical stimulation (pacing). The 
system was calibrated with the help of Prof. JC Kentish, using a novel technique that 
uses a single diffraction grating of 8.0 µm spacing to check the linearity of the system 
over a range of sarcomere lengths. The grating was visualised using the x40 objective 
and the FTT of the striation of the grating was demonstrated on the computer screen as 
sinusoidal waves evenly spaced. We used 6 peaks to calibrate the system.  
 
Figure  2.3: Isolated myocyte displayed on IonOptix screen; FTT power line (red) 
 
2.3.4 Apparatus for intracellular calcium measurement 
Intracellular calcium was measured using the IonOptix system (Figure  2.1) with the SL 
measurements in the intact myocyte experiments. The light from the Xenon arc lamp 
was passed through a hyperswitch filter so the myocytes loaded with the relevant 
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fluorescence detector (fura-2 AM (Calbiochem) in our experiments) were excited 
alternately at two wavelengths (340 and 380 nm). The excitation light was reflected 
onto the myocyte in the bath using a dichroic mirror via the objective x40 lens. The 
fura-2 fluorescence was then collected and passed through a 510 nm filter onto the 
photomultiplier to be detected. The fura-2 fluorescence was passed from the 
photomultiplier to a Cairn Spectrophotometer (Cairn Research, Kent, UK). The 
spectrophotometer averaged the 340 and the 380 filtered signals and the 340/380 ratio 
was then calculated and recorded using IonOpix (Figure  2.4). The Ca transient 
amplitude (Catr) was calculated by subtracting the average calcium measurement at the 
end of each relaxation from its level during contraction. 
 
Figure  2.4: Ionoptix recording of the SL and the Catr with the event marker indicated 
 
2.3.5 Protocol for the intact cell experiments 
Myocytes were incubated with fura-2 at a concentration of 2 µM in Tyrode solution for 
10 minutes and then the fura-2 solution was removed and the cells were resuspended in 
the Tyrode solution and loaded in the system bath (Figure  2.1). After washing the lines 
and loading them with desired solutions, the bath is filled with the Tyrode solution. The 
fura-treated cells were then loaded in the bath and electrically stimulated at 1 Hz (unless 
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2.3.6 Skinned myocyte perfusion system 
The cell perfusion set-up was adapted from the method described by Lim and 
colleagues. (Lim et al. 2001) and a schematic of the system is shown
 
in Figure  2.5. The 
SF-77B Perfusion Fast-Step system was supplied by Warner Instruments (CT, USA). A 
single skinned myocyte was gravity-superfused using a three-barrel square glass pipette. 
A stepper motor was attached to the three-barrel pipette, which served to rapidly switch 
between adjacent barrels (Figure  2.5 B). The rapid response and low hysteresis of the 
stepper mechanism allowed for very fast switching times. The three-barrel pipette and 
stepper motor were attached to micromanipulators to allow precise placement of the 
pipette tip over the myocyte (Model MN; Narishige Co. Ltd., Tokyo). Up to six 
different solutions were connected to a single input manifold (which in our experiments 
were maximal activating solutions with increasing calcium concentration). The 
contraction generated by increasing the superfused calcium concentrations was 
measured using IonOptix SL measurements as described. The flow through the barrels 
was kept constant at ~250 µl/min by adjusting the height of the manifold system. This 
was measured by recording the decrease in volume of solution in the reservoirs over a 1 
min period. This rate of flow prevented mixing of solutions from adjacent barrels, 
which allowed a single myocyte to be perfused by one solution 
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Figure  2.5: Schematic diagram of the perfusion system. A. A 3-barrel pipette was 
used for perfusion. B. A stepper motor was used to rapidly switch between solutions 
bathing the myocyte. C. A tap-controlled manifold system was attached to the 
stepper motor. D. Myocytes were perfused in a custom-made bath. Reproduced from 
Lim et al. (2001) (Lim et al. 2001) 
2.3.7 Skinned myocytes experimental protocols 
The skinned myocytes were superfused with alternating relaxing and activating 
solutions at a rising calcium concentration using the stepper-motor. The SL during 
contraction (Figure  2.6) caused by the rise in calcium in the activating solution was 
measured with IonOptix and the SL relationship with pCa was analysed. 






Figure  2.6: Example of skinned myocyte SL shortening induced by rising 
concentration of calcium (experiment recorded using IonOptix) 
Time (s)
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2.4 Patch clamping experiments 
2.4.1 System set up  
Rat ventricular myocytes (isolated as described earlier) were placed in a 2 ml bath on 
the stage of an inverted microscope (Nikon) with a x40 objective, and also viewed 
through a Nikon video camera connected to a monitor with larger magnification. The 
electrode pipettes were attached to a micromanipulator positioned above the bath. The 
fine movement of the micromanipulator as well as the higher magnification of the video 
camera helped in applying the pipette to the surface of the myocyte with accuracy. 
Patch pipettes were pulled from capillary glass with filament (GC150TF-10, Harvard 
apparatus Co., Novato, CA) using DMZ-Universal Puller (Zeitz pullers, Augsburg, 
Germany). Pipettes exhibited 1.5 to 2 MΩ resistance when filled with the pipette 
solution. Currents were filtered at 1 kHz
 
and sampled at 5 kHz. Current acquisition was 
performed using pCLAMP10
® 
and analysed using CLAMPFIT
®
 (Axon Instruments, 
Foster City, CA). All recordings were initiated only after 2 minutes to allow
 
complete 
dialysis of the cytoplasm with a seal resistance not less than 250 MΩ. 
 
Figure  2.7: Rat ventricular myocyte with patch pipette 
 
2.4.2 Experimental protocol 
These studies were used to measure L-type calcium current (ICa,L) measurements and the 
INa. For the ICa,L  measurement the external solution was perfused at 34
o 
C. The INa 
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current was inactivated to be able to measure the much smaller ICa,L  using a step from  
-70 mV to -40 mV and the K
+




 in the 
pipette solution. ICa,L
 
(measured as the peak inward current) was elicited by a step 
depolarisation
 
from -40 mV to voltages in the range -30 mV to +50 mV at a frequency 
of 5 Hz for 200 ms. For INa measurements, the external solution was superfused at 23
o
C 
only (it was not possible to maintain consistent seals for the length of the experiment at 
34
o
C) (Figure  2.8). We used holding potentials of -90mV and the current was elicited by 
stepping to -50 mV at a frequency of 5 Hz for a 100 ms. This was after performing an 
IV relationship study (from -70 to +10 mV) and established the peak current at -50 mV. 
Currents were sampled at 10 kHz and filtered at 5 kHz. 
 
Figure  2.8: Schematic representation of the ruptured-patch technique showing the 
composition (in mM) of the internal and external solutions for the ICa,L experiments (left) 
and the INa experiments (right). 
 
2.5 Langendorff perfused rat heart experiments 
2.5.1 Harvesting of hearts 
Rats were anaesthetised using intraperitoneal injection of pentobarbitone sodium (60 
mg/kg). The femoral vein was exposed and 50 IU of heparin was injected to prevent 
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thrombus formation in the microcirculation of the heart. The chest was then opened 
through a top-roof incision in the abdomen and the heart was exposed, excised by 
transecting the major vessels leaving a relatively long part of the aorta attached to the 
heart for perfusion and immediately immersed in ice-cold KHB solution (4
o
C) to arrest 
and protect the heart. The heart is then attached to the perfusion cannula via the aorta 
and perfused with 95% O2: 5% CO2 gassed KHB at a temperature of 37
o
C and 
controlled pressure of 100 cm of water within 30-60 seconds of harvest. 
2.5.2 Langendorff perfusion system and setup 
The isolated hearts are attached to a stainless steel cannula with circumferential 
grooves. The heart can be perfused with different solutions stored in elevated reservoirs 
providing a perfusion pressure of 100 cm of water. All glassware used were water 
jacketed for temperature control. The function of the heart is measured by inserting a 
water-filled balloon (constructed from cling film tied on the end of a catheter) inside the 
left ventricle. The balloon is connected to a pressure transducer and the pressure trace is 
recorded via a bridge amplifier using the Powerlab
®
 system (ADI Instruments 
Chalgrove, Oxford, UK). Electrocardiogram (ECG) was also recorded using a silver 
wire connected to Powerlab
®
 by a bio-amplifier. The balloon volume was adjusted 
during the stabilisation to achieve an end-diastolic pressure between 4-8 mmHg. The 
left ventricular developed pressure (LVDP) was electronically calculated from the 
difference between systolic and diastolic pressure. The heart rate was electronically 
calculated from the time of the cyclic change in the more stable pressure trace rather 
than the ECG signal which was prone to noise and sensitive to interference. However, 
ECG was always monitored to insure the lack of any electrical activity during arrest and 
to measure atrial activity during ventricular arrest and atrio-ventricular dissociation. The 
heart is kept in a water-jacketed glass reservoir covered with paraffin film ‘parafilm’ to 
maintain the temperature. The coronary perfusate was collected and the flow was 
calculated on a regular basis. Hearts were left to stabilise for 20 minutes with KHB 
perfusion at 37
o
C, and they were included in the study if heart rate was between 200 and 
400 bpm, LVDP between 100 and 180 mmHg and coronary perfusate between 10 and 
16 ml/min.  
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2.6 Statistical analysis 
Data are presented as mean ± standard error. Difference between means was analysed 
by paired t-tests or ANOVA with post-hoc Dunnet’s test for multiple group comparison 
where appropriate. In the concentration-response graphs, the values were expressed as a 
percentage of control (no drug) and the sigmoid curves were fitted using GraphPad 
Prism software to the following equation: Y= Ymin + (Ymax-Ymin)/(1+(IC50/X)
-n
) where X 
is the drug concentration, IC50 is the concentration for 50% of the maximal inhibition, 
and n is the Hill coefficient 
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CHAPTER 3. RESULTS 1: THE NEGATIVE INOTROPIC 
EFFECT OF ESMOLOL IN THE ISOLATED MYOCYTES 
3.1 Introduction 
We (Bessho and Chambers 2001) previously showed that esmolol at ( a concentration of 
0.3 mM) had a significant inhibitory effect on contraction (Figure  1.13), with a 75% 
decrease in LVDP. The effect on heart rate, however, was less dramatic with only a 
20% decrease. Clinically, esmolol has been used in combination with blood-based 
preparation as an alternative to conventional cardioplegic arrest with the crystalloid 
Bretschneider solution (Mehlhorn et al. 1999) or with blood hyperkalaemia (Scorsin et 
al. 2003). Both studies reported that esmolol significantly inhibited myocardial 
contraction with an initial infusion concentration estimated to be around 0.4-0.7 mM 
directly into the coronary arteries, which allowed them to operate on the heart despite 
the fact that the heart rate was maintained at around 30-45 bpm. The negative inotropic 
effect of esmolol was presumed to be due to its β-blocking action; however, it is 
unlikely that the β-blocking effect can induce such profound negative inotropy. This 
hypothesis is confirmed by Bessho’s findings (Bessho and Chambers 2001) (Figure 
 1.13) where this negative inotropic effect was demonstrated in Langendorff perfused 
hearts with no catecholamine background. Additionally, the pilot data demonstrated that 
esmolol at 1mM induced arrest in the paced isolated ventricular myocyte where again, 
there is no background adrenergic stimulation. This effect was not observed with the β-
blocker atenolol at the same concentration of 1 mM (Figure  1.14). This pilot data also  
demonstrated that the calcium transient (Catr) decreased by about 50%, which would 
explain the profound negative inotropic effect observed in the experimental studies by 
Bessho and the clinical studies by Scorsin (Scorsin et al. 2003), Melhorn (Mehlhorn et 
al. 1999) and others (Kuhn-Regnier et al. 1999; Kuhn-Regnier et al. 2002). It is, 
however, difficult to understand the complete arrest by in our pilot experiment. 
Consequently, this chapter aims to examine in detail the negative inotropic and Catr 
inhibitory effects of esmolol in the electrically stimulated isolated rat ventricular 
myocytes. 




Experiments were conducted in isolated rat ventricular myocytes loaded with Fura-2, 
for the measurement of cell contraction and the calcium transient as detailed in Methods 
(Section  2.3 ). In all experiments, each myocyte was chosen to fit the inclusion criteria 
of having a rod shape with no membrane blebs and the diastolic sarcomere length (SL) 
between 1.7 and 2.0 µm while being superfused with Tyrode solution at the desired 
temperature in the perfusion bath. The sarcomere shortening (SS) and Catr were 
measured for at least 10 seconds as control after a period of 90 seconds for stabilisation. 
Then, the treatment was applied at the desired concentration by switching the 
superfusion solution using the multiple channel manifold (see details in Section  2.3.3). 
After reaching the steady state (usually within 3 minutes of superfusion) the Catr and the 
SS were measured again to study the effect. The desired treatment then was applied by 
switching the superfusion solution from Tyrode to the desired drug diluted in Tyrode 
solution at the desired concentration. To ensure that the observed effect is caused by the 
treatment and to determine the reversibility of the treatment, washout period with 
Tyrode solution for up to 5 minutes is conducted and SS and Catr recorded again to 
demonstrate recovery. After this measurement is completed the myocytes in the bath 
were washed out thoroughly and another aliquot of fresh myocyte suspension was used. 
 
3.3 Results 
3.3.1 The negative inotropic effect of esmolol (1 mM) 
The inotropic effect of esmolol was initially studied in the electrically-stimulated intact 
isolated rat ventricular myocyte to reproduce the effect demonstrated in the pilot data, 
without the fluorescence dye. In these experiments the excitation light from the arc lamp 
and the hyper-switch were turned off and IonOptix recorded only the SL.  
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Esmolol (1 mM) was superfused for 120 seconds at room temperature and the esmolol 
effect on SS was calculated from the last 10 seconds. Finally, the reversibility of 
esmolol was studied by superfusing the myocytes with Tyrode again for up to 5 minutes 
until reaching a steady state to allow adequate washout of esmolol and the washout 
effect on SS was calculated from the last 10 seconds of the recording. Nine myocytes 
were studied in these experiments (n=9). Esmolol (1 mM) had an extensive negative 
inotropic effect on contraction, as shown by a decrease of 86.8 % in SS from the control 
value of 0.19 ± 0.03 µm (mean ± SE) to 0.03 ± 0.01. SS partially recovered to 59% of 
control to 0.11 ± 0.03 µm (Figure  3.1). This suggested that the negative inotropic effect 
of esmolol demonstrated by our single experiment in the pilot data was reproducible. 
Interestingly, during the treatment with esmolol the threshold of excitation in order to 
generate contraction became higher and occasionally the pacing voltage had to be 
increased significantly in order to induce excitation and contraction. We observed this 
in all the following paced isolated myocytes studies later. The underlying mechanism of 
this incidental finding was later explained in Chapter 7. However, the next step was to 
establish the effect of esmolol on the calcium transient in conjunction with its effect on 
contraction 
 
Figure  3.1: The effect of esmolol on contraction in the electrically stimulated intact 
isolated rat ventricular myocytes. This effect is partially reversible in the washout 
period n=9. 
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3.3.2 Effect of esmolol (1 mM) on Catr and SS  
After establishing the negative inotropic effect of esmolol (1 mM) in the isolated 
ventricular myocytes, these experiments were performed to reproduce the effect of 
esmolol (1 mM) on SS and Catr using fura-2-loaded myocytes. This was previously 
demonstrated in our pilot data using different Ca
2+
 sensitive dye, Indo-1. Esmolol had 
the same negative inotropic effect on contraction within a few seconds of introduction. 
Esmolol also decreased the intracellular calcium Catr (Figure  3.2,Figure  3.3, Figure  3.4). 
Esmolol (1 mM) made a few cells completely unexcitable despite using maximum 
voltage potentials (40 volts), Catr was fully abolished (Figure  3.2); However, most cells 
exhibited a partial negative effect on contraction and Catr (Figure  3.3Figure  3.4). In the 
pilot data, complete arrest in contraction was induced by esmolol (1 mM), but the Catr 
was not completely abolished; this was different to the present results, where esmolol 
arrest completely abolished Catr (Figure  3.2). 
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Figure  3.3: Example of myocyte treated with esmolol (1mM) with negative effect on 
contraction and Catr without inducing full arrest.  
 
Figure  3.4: The negative inotropic effect of esmolol (1 mM). Effect on sarcomere 
shortening (A) and the fura-2 fluorescence ratio (Catr ), (B). Top panels: typical chart 
records showing the rapid fall of contraction. Middle panels: example contractions 
and Ca
2+
 transients. Lower panels: averaged data for the amplitudes of sarcomere 
shortening and the Ca
2+
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3.3.3 Effect of esmolol on ionised calcium 
The previous experiments suggested that esmolol inhibited contraction by inhibiting 
Catr. However, an alternative possibility is that esmolol, or another compound in the 
Brevibloc
®
 preparation, could have chemically decreased the availability of ionised 
calcium in the perfusate by having a calcium chelating effect. Any calcium chelating 
effect will decrease ionised calcium in the extracellular space, which decreases the ICa,L  
via the L-type calcium channel. This will subsequently decrease the availability of 
ionised calcium in the intracellular space to trigger the calcium-induced calcium-release 
from the SR, leading to a decrease in Catr and contraction. It is therefore important to 
determine whether esmolol or any other compound in the Brevibloc
®
 preparation has 
any chelating effect, which might explain these findings before performing further 
studies to establish, which cellular targets might be involved in this effect.  
In order to investigate the chelating effect of Brevibloc
®





] was measured in both Tyrode (1mM CaCl2) solution and Tyrode + Brevibloc
®
 at 
an esmolol concentration of 1mM using a blood-gas analyser. The [Ca
2+
] was 1.15±0.2 





] in the 2 solutions was not significant, which strongly suggests that 
the inhibitory effect of esmolol on the calcium transient demonstrated above is not 
achieved by directly chelating extracellular ionised calcium. 
3.3.4 Esmolol vs. atenolol 
It was important to determine whether the effects seen with esmolol were common to 
other β-blockers. Hence, we conducted experiments in, which investigated the effect of 
another β blocker (atenolol) on the Catr and SS. In addition, the effect of esmolol was 
studied in the presence of atenolol, when the β-receptors should be blocked and the 
effect of esmolol should be altered if it was mediated by the β-receptors. As above, 
intact isolated rat ventricular myocytes loaded with fura-2 were superfused with Tyrode 
solution for a 90 seconds stabilisation period and the control values of Catr and SS were 
calculated from the last 10 seconds. Subsequently, atenolol (1 mM) in Tyrode solution 
was perfused for 5 minutes to ensure the recording of any delayed effect of atenolol (in 
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a separate pilot study atenolol had no effect if the cells were treated with atenolol for 
over 15 minutes). Then, on the background of continuous atenolol perfusion, 1 mM 
esmolol was perfused in the myocyte bath for at least a further 2 minutes after reaching 
the steady state.  Figure  3.5 shows an example trace of the effect of atenolol alone and 
esmolol + atenolol. The myocyte SS during treatment with atenolol (0.26±0.04 µm) was 
not significantly different from the control SS (0.24±0.04 µm P=0.12), while with 
atenolol + esmolol, the SS decreased by 65% to 0.09±0.02 µm (P<0.0001). For the Catr, 
the control and atenolol values were not significantly different (0.11 ± 0.04 and 0.12 ± 
0.04 respectively, P=0.12), while Catr dropped by 50% with atenolol+esmolol to 0.06 ± 
0.03 (P<0.0001) (Figure  3.6). 
These results demonstrate that the effect of esmolol on Catr and SS is not shared or 
altered by another β-blocker, atenolol; this strongly suggests that the negative inotropic 
effect of esmolol does not require functioning β receptors. 












































Figure  3.5: Example trace of the lack of β1-adrenoceptor participation in the effect of esmolol. Atenolol (1 mM) had no effect on SS (top) 
or Catr (bottom). Meanwhile adding esmolol (1mM) inhibited contraction and Catr.   



























































Figure  3.6: Lack of β1-adrenoceptor participation in the effect of esmolol on A: 
Sarcomere shortening and B: Calcium transient. The effect of atenolol (1 mM) vs. 
atenolol + esmolol (both 1 mM). Control was with no drug added. * P<0.0001 (n=5/ 
group).  
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3.3.5 The concentration-response curve of the effect of esmolol on isolated 
cardiac myocytes at 23
o
 C
Having established that the observed effects of esmolol on SS and Catr were not caused 
by calcium chelation or a general characteristic of β-blockers, we were interested to 
determine the concentration-response effects in isolated myocytes. The studies were 
conducted at 23
o
 C (room temperature) as this temperature would be used clinically for
cardioplegic solution. We also investigated this effect at 34
o
 C as this is close to
physiological normal temperature. The experiments were performed to determine the 
millimolar concentrations-response relation for both contractility and the Catr. We used 
4 concentrations for these experiments: 0.03, 0.1, 0.3 and 1 mM. The fura-2 loaded 
myocytes were perfused as above for the 90 second-stabilisation period with Tyrode and 
control Catr and SS were measured, then each cell was randomised into one of the four 
above mentioned groups of different concentration of esmolol and perfused for 2 
minutes. A single cell per concentration was studied with a fresh cell suspension was 
used every time to ensure that each cell was only treated with a single concentration of 
esmolol. To measure the reversibility from esmolol inhibition, SS and Catr were 
measured after washing esmolol for 3 minutes in Tyrode (recovery). Five cells were 
included in each group; Catr and SS were normalised to the control value. The data 
shows that, with increasing esmolol concentrations, there is a progressive decline in 
both SS and Catr (Figure  3.7); The data is plotted as a concentration response curve with 
the best sigmoid fit (using Prism
®  
statistical analysis) using the equation mentioned in
the Method Section  2.6. From this curve the IC50 for the SS was 0.13±0.04 mM. (Hill 
coefficient = -1.6 ± 0.6) while the IC50 of Catr was 0.16±0.02 mM. (Hill coefficient = -
1.3± 0.19). 




















Figure  3.7: Concentration-response curves. The effect of esmolol on contraction and 
calcium transients at 23
o 
C (n=5/group)
3.3.6 The concentration-response curve of the effect of esmolol on isolated 
cardiac myocytes in 34
o
 C
The negative effect of esmolol on contraction and Catr was demonstrated at 23
o
C
earlier; this is a preferred temperature used for cardioplegia (the main application of 
esmolol at millimolar concentrations). However, it is essential to investigate whether 
esmolol will maintain the same effect in more physiological temperature. At 37
o
C, the
myocytes tend to die more quickly, therefore 34
o
C was selected to be used as a
temperature close to physiological and similar experiments to those described earlier 
were repeated at 34
o
C.





sigmoid concentration-response curve was constructed (Figure  3.8) and the IC50 for SS 
was 0.16±0.02 mM (Hill coefficient = -1.04±0.06) while the IC50 of Catr was 
0.24±0.05mM (Hill coefficient =-1.14±0.2). 




















Figure  3.8: Concentration-response curves. The effect of esmolol on contraction and 




Esmolol as highly selective β1-blocker is expected to have a negative inotropic and 
chronotropic effect. This effect was assumed to be the mechanism behind the “minimal 
myocardial contraction” in the clinical studies, which used esmolol as an alternative to 
conventional cardioplegia. However, any possible effect of esmolol as a beta blocker in 
the isolated hearts is likely to be negligible due to the nature of the sympathetic 
innervation of the heart (Kuhn-Regnier et al. 1999; Mehlhorn et al. 1999; Kuhn-Regnier 
et al. 2002; Scorsin et al. 2003); in the Langendorff rat hearts for instance (Bessho and 
Chambers 2001; Bessho and Chambers 2002) any possible adrenaline to be 
counteracted by esmolol would have been through the blood stream via coronary 
circulation from the adrenal glands (Drake 2005) On the other hand the less relevant 
catecholamine, noradrenalin, is mainly an Alfa receptor agonist with minimal direct 
effect on contraction. Noradrenalin is released in the heart by the axon endings of the 
thoracolumbar chain neurons rather than within the heart itself which makes a 
Langendorff perfused heart very low in catecholamine contents and by perfusing these 
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hearts during the stabilisation period most of these catecholamine compounds would 
have been washout out. Therefore esmolol is likely to have exerted its effect 
independently from any other catecholamine in the heart. The profound negative 
inotropic effect achieved by esmolol in these studies was much more than the expected 
effect of a β-blocker and suggests that esmolol had a direct inhibitory effect on 
contraction in addition to reducing heart rate to 30-40 bpm in these patients. As shown 
in Section  3.3.4, esmolol induced its negative inotropic action on the electrically 
stimulated rat ventricular myocyte despite a background infusion of the other β1-
blocker, atenolol which seems to suggest that this effect is not related to the β1-receptor. 
Some non-selective β-blockers could act directly as inverse agonists (Baker et al. 2003); 
however, this tends to occur at much lower concentrations (nano-µM) (Harding SE 
2004). Additionally, esmolol, like atenolol, is a very selective β1-receptor antagonist 
and there is no evidence for inverse agonist effect in β1-receptors. Furthermore, an 
inverse agonist effect does not explain the complete abolition of contraction (Figure  3.2) 
or the reduced excitability, which resulted in the increased threshold of excitation 
mentioned in Section  3.3.1. Therefore, these findings confirm that esmolol has a direct 
inhibitory effect on contraction. There is also an inhibitory effect on the Catr, which can 
wholly or partially explain this negative effect. However, the inhibition of Catr seems to 
be less prominent than that on contraction as shown in Figures  3.7 and  3.8. It is well
known that the relationship between Catr and contraction is not linear (Bers 2002); 
however, discrepancy may still indicate that the myofilament sensitivity to intracellular 
calcium might have been reduced by esmolol. In particular, the pilot data (Figure  1.14) 
also showed almost complete abolition of contraction with esmolol, but only partial 
reduction of Catr after esmolol superfusion. It was important, therefore, that we 
investigated whether esmolol acts by reducing the myofilament sensitivity as part of its 
negative inotropic effect. The studies in the following two chapters are aimed 
at exploring the mechanism of Catr reduction and any possible effect of 
myofilament desensitising effect of esmolol. 
3.5 Summary and Key Findings 
We have demonstrated that esmolol inhibited contraction in the isolated paced 
myocytes. This effect was maintained with a background treatment of atenolol. 
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Subsequently, we loaded the myocytes with Fura 2 and esmolol inhibited contraction 
and the calcium transient in a dose dependent manner and maintained in both room 
temperature and more physiological (34) temperature. We also excluded any possible 
chelating effect to calcium esmolol might have had. 
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CHAPTER 4. RESULTS 2: THE EFFECT OF ESMOLOL 
ON THE SARCOPLASMIC RETICILUM 
 
4.1 Introduction 
In the previous chapter, we demonstrated that, in isolated cardiac myocytes, esmolol 
superfusion inhibited contraction by reducing sarcomere shortening (SS) and 
intracellular calcium transient (Catr). As explained in Sections  1.5.3 and  1.5.5, the rise 
of intracellular calcium during the excitation-contraction coupling takes place at two 
levels: initially, entry of extracellular calcium via the activated L-type calcium channels 
occurs during the plateau phase of the action potential (Bers 1991; Bers 2002), and this 
leads to intracellular calcium-induced calcium-release from its storage in the 
sarcoplasmic reticulum (SR) (Bers 1991; Bers 2002). Other β-blockers like propranolol 
were shown to inhibit the uptake of calcium by the SR (Hess et al. 1968). This suggests 
possible effect of esmolol on the SR, which results in less intracellular release of the 
calcium during excitation. The aim of these studies was to determine whether esmolol 
exerted any effect on the SR. In order to investigate this, we studied the negative 
inotropic effect and the Catr of esmolol in the isolated ventricular myocytes after 
chemically inhibiting the SR with Thapsigargin pre-treatment. If the SR is involved in 
the effect of esmolol this inhibitory effect would be modified. 
4.2 Methods 
After isolation rat ventricular myocytes (Section  2.3.1), they were treated for 10 minutes 
with the SR blocker thapsigargin (1µM) diluted in Dimethyl sulfoxide (DMSO). This 
will result in irreversible inhibition of the calcium release from the SR (Kijima et al. 
1991). It also inhibits the uptake of calcium via the sarco/endoplasmic reticulum Ca
2+
 
ATPase (SERCA) (Kijima et al. 1991; Lytton et al. 1991). The myocytes were loaded 
with fura-2 in a similar manner explained in the previous chapter. Once again the effect 
of esmolol on contraction and Catr was studied by electrically stimulating these 
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myocytes and measuring contraction and Catr using IonOptix system (Section 2.3.5). 
Provisional experiments were conducted to exclude any unexpected effect of the solvent 
DMSO by treating myocytes with DMSO only for 10 min before washing. Myocytes 
pre-treated with DMSO showed no alteration in the calcium transient or the contraction. 
Meanwhile, thapsigargin pre-treated myocytes had a profound negative inotropic effect 
and extremely reduced Catr as expected. To overcome the large negative inotropic effect 
caused by blocking the SR, the extracellular calcium in the Tyrode solution was 
increased to 7 mM as this was found to be the concentration required to restore the 
contraction to normal values in cells with intact SR, which is around 0.2µm of 
sarcomere shortening. During this experiment, extra care was taken to insure that the 
calcium was desolved in the solution. In addition to blocking the calcium-induced 
calcium-release, thapsigargin also blocks the SERCA (Kijima et al. 1991; Lytton et al. 
1991), which is responsible for the uptake of the free intracellular Ca
2+
 at the end of 
plateau phase. This meant that the drop in calcium will be much longer, which results in 
a prolonged plateau phase and, therefore, prolonged action potential in these myocytes. 
The high calcium entered into the cells during the excitation process was dependent 
entirely in this situation on the Na/Ca exchanger. Therefore, the cells were paced at 0.1 
Hz instead of 1 Hz to allow enough time for the Na/Ca exchanger to remove the 
intracellular calcium and prevent tetanisation of the myocytes. With the increased 
extracellular [Ca
2+
] in the superfusate and the reduced pacing rate, the calcium transient 
were measured the in the isolated rat ventricular myocytes loaded with Fura-2 (Section 
 2.3 above. The response to esmolol in thapsigargin treated group was compared with 
myocytes with intact SR, which were superfused as described in the last chapter with 
extra cellular Ca
2+
 of 1 mM in the superfusate of  KHB followed by KHB + esmolol 
(0.3mM) and paced at 1 Hz. In brief, Myocytes were selected to fit the inclusion criteria 
of having a rod shape with no membrane blebs and the diastolic sarcomere length (SL) 
between 1.7 and 2.0 µm while being superfused with Tyrode solution at 23
o
C in the 
perfusion bath. At least 5 contractions were used to calculate the average value of 
contraction presented by the sarcomere shortening (SS) and Catr at every stage, pre-
treatment baseline, contraction, and recovery. 
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4.3 Results 
4.3.1 The effect of esmolol on cardiac myocytes with blocked SR 
A single dose of esmolol (0.3mM) was chosen because it caused a decline in Catr and 
contraction of around 40-60% of the control value (from previous experiments). The 
effect of esmolol in the myocytes with the blocked SR was compared with its effect in 
the intact SR myocytes, which were superfused with Tyrode solution containing 1 mM 
of extracellular calcium in a similar experimental conditions to those used in the 
previous chapter. Again the SS and Catr during esmolol treatment period were 
normalised to the pre-treatment control value. The effect of esmolol shown previously 
in the intact myocytes was maintained in the myocytes treated with thapsigargin (Figure 
 4.1). Esmolol (0.3 mM) reduced SS in the intact SR group to 32±4 % of control 
compared with 39±8% in the blocked SR group. It also decreased Catr to 57±4 % in the 
intact SR group compared with 56±8% (Figure  4.2). The effect of esmolol in the two 
groups on both SS and Catr was not statistically significantly different using unpaired t-
test (p=0.3 and 0.8 for Catr and SS, respectively). 




Figure  4.1: Example trace of the lack of the sarcoplasmic reticulum participation in the effect of esmolol. (0.3mM) inhibited contraction and 
Catr in isolated rat ventricular myocyte treated with thapsigargin. The control contraction and Catr were restored by increasing the 
extracellular calcium to 7 mM and to avoid tetanising the cells, the pacing rate was decreased to 0.1 Hz. 





Figure  4.2: The role of the SR in the effect of esmolol. Inhibitory effect of esmolol 0.3 
mM on contraction and calcium transient  in myocytes with functional SR or 
myocytes treated with 1 M thapsigargin (n=5/group). All data expressed relative to 
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4.4 Discussion 
As demonstrated above, the inhibitory effect of esmolol on contraction and the Catr was 
maintained in the myocytes with inhibited SR. It was also comparable to the effect in 
the myocytes with intact SR. Other β-blockers were shown to inhibit the SR uptake of 
calcium at high concentrations (atenolol 1mM) an effect was shared to a less extent with 
other alpha blockers (Hess et al. 1968) (Cantilina et al. 1993). This was thought to be by 
inhibiting the SERCA (Hess et al. 1968) (Cantilina et al. 1993). However, in these 
experiment the SERCA was already blocked, which was demonstrated by the delayed 
relaxation, which confirms that the inhibiting effect of Catr is independent form the SR. 
Therefore, we can speculate that the L-type calcium channels are the likely target by 
which esmolol blocked the calcium entry to the cell or what is known as the ICa,L 
current. The effect of esmolol on the L-type calcium channels will be studied in chapter 
6. However, initially, it was important to determine whether esmolol influence
myofilament sensitivity to calcium, the mechanism suggested by the pilot data (Figure 
1.14) and the dose response relationship (Figures  3.7 and  3.8). This will be described
next. 
4.5  Summary and Key Findings 
This Chapter aimed at identifying any possible involvement of the SR in the inhibitory 
effect of esmolol on the calcium transient. We demonstrated that this effect was 
maintained in SR depleted myocytes which suggests that the esmolol inhibitory effect 
on contraction and the calcium transient is not dependent on the SR.  
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CHAPTER 5. RESULTS 3: THE EFFECT OF ESMOLOL 
ON MYOFILAMENT SENSITIVITY TO CALCIUM 
5.1 Introduction 
The protective effect of chronic use of β-blockers against ischaemia was well 
established through different mechanisms (Harding SE 2004; Purek et al. 2006). 
However, recently long term treatment of β-blockers (bisoprolol) prior to ischaemic 
events was shown to restore the myofilament sensitivity to calcium and resistor 
myofilament contractility in the remote myocardium (Duncker et al. 2009). Meanwhile 
myofilament desensitisation with BDM was shown by us to improve the protective 
effect of polarised arrest against ischaemia in the cold storage (Snabaitis and Chambers 
1999). This highlights the importance of investigating any possible effect esmolol might 
have on the myofilaments. Earlier studies described in Chapter three showed that 
esmolol decreased Catr in a dose dependent manner and that this effect was not 
abolished by blocking the β-receptors with atenolol (Section  3.3.4). We also showed 
that the inhibition of contraction (SS) by esmolol was more profound compared with 
Catr inhibition with the IC50 for contraction inhibition being 0.16±0.02 mM vs. 
0.24±0.05 mM for inhibition of the Catr (Sections  3.3.5 and  3.3.6). This can be 
explained by the non-linear relationship between the intracellular calcium concentration 
and contraction (Solaro and Rarick 1998; Bers 2002) but could also suggest that 
esmolol could have a direct effect on the myofilament’s sensitivity to calcium. A 
desensitising effect could also explain the results obtained in our pilot data (Figure  1.14) 
where 1mM esmolol abolished contraction (measured using edge detection method in 
an isolated cardiac myocyte loaded with the calcium fluorescence dye Indo-2) without 
abolishing the calcium transient completely. This study, however, has an important 
limitation that it was only performed on one cell (n=1); these findings were not 
reproducible in our detailed studies described in Chapter three, where every time 
esmolol induced complete arrest in an isolated cardiac myocyte the calcium transient 
was also abolished. Any desensitisation effect, however, cannot be excluded despite the 
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inability to reproduce these preliminary findings. The aim of the experimental work in 
this chapter is to study the effect of esmolol on the myofilaments sensitivity to calcium.  
5.2 Methods 
5.2.1 The intact myocytes experiments 
The gold standard method in assessing the myofilament sensitivity to calcium is the 
skinned myocytes. However, we developed this method to assess any possible 
desensitising effect of esmolol on the myofilaments to calcium in the intact myocytes, 
which offers more physiological conditions. The myofilament sensitivity to calcium was 
studied in the isolated rat ventricular myocytes using the preparation described earlier in 
Sections  2.3.4 and  2.3.5. In brief, the isolated myocytes were loaded with Fura-2 and 
placed in the superfusion bath. A myocyte, which fits within the inclusion criteria was 
selected. After a period of stability contraction and Catr were recorded. Subsequently, 
we studied the relationship between the calcium transient (Catr ) and contraction (SS) by 
gradually reducing extra-cellular calcium through switching the superfusion solution 
from the usual Tyrode with [Ca
2+
] of 1 mM to Tyrode solution with [Ca
2+
] of 0.5 mM
and then to 0.3 mM. This decline in extra-cellular calcium leads to gradual decrease in 
Catr and subsequently contraction by having less available intracellular calcium to the 
myofilaments, which reduces contractions. This resulted in gradual reduction in 
contraction and Catr to around 40-60% from baseline. This gradual decline is recorded 
generating multiple data points representing the Catr /SS relationship in the untreated 
myocyte. Subsequently, extracellular calcium wass restored again with normal calcium 
(1mM)-Tyrode for a few minutes until reaching baseline. After a period of steady state, 
the same myocytes is then treated with Tyrode + esmolol 0.3 mM. The gradual decline 
in contraction and Catr over 4 or five beats was again recorded. The data points, which 
represent the relationship between each Catr value and SS after treatment of esmolol 
was again plotted and compared between the negative inotropic effect of declining 
extracellular calcium and the negative inotropic effect of esmolol. The experiment was 
repeated using four cells. The advantage of this technique is to explore any individual 
effect of esmolol on desensitisation in a physiological environment where all the 
organelles of the myocytes are intact. Meanwhile there were some limitations in this 
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technique as the decline in Catr and SS was faster in the esmolol group, which resulted 
in fewer data points in the middle range of Catr measurements. Equally, the inhibitory 
effect of esmolol 0.3 mM seemed to be more profound after exposing the myocyte to a 
period of hypocalcaemia.  
5.2.2 The skinned myocytes experiments 
The methods using skinned myocytes were explained in details in Sections  2.3.2,  2.3.6 
and  2.3.7. To summarise, skinned myocyte model is the gold standard method to study 
the myofilament sensitivity to Ca
2+
as it directly measures the relationship of [Ca
2+
]i with 
contraction presented by Sarcomere Length (SL) without the cell membrane and 
therefore overcome the limitations mentioned above. However, one can argue that 
myofilaments interaction with calcium in isolation of other organism is not 
physiological and could miss out on any possible intracellular modification esmolol 
might have, which depends on other intracellular organelles. In order to mitigate for 
such limitations we performed two sets of experiments; the first set is to study any 
direct effect of esmolol on the myofilaments after crossing the cell membrane. 
Therefore esmolol 0.3 mM was added to the relaxing and activating solutions and the 
effect of perfusing the myofilament with these solutions were compared with 
myofilaments perfused with esmolol free relaxing and activating solution. The second 
experiment was performed to examine whether esmolol might instead alter myofibrillar 
Ca
2+
 sensitivity by post-translational modifications (e.g. phosphorylation) in the intact 
cell; therefore, we treated intact myocytes with esmolol (0.3 mM) for 10 minutes before 
skinning. Subsequently, the myocytes were skinned and then the myofilaments 
sensitivity to calcium was studied and compared with untreated skinned myocytes. The 
calcium sensitivity measurements was performed by suspending the skinned myocytes 
in a cytosol like relaxing solution and few drops were placed in the cell perfusion 
system. The perfusion system allowed a large number of cells to be screened without 
the need for measuring isometric contractile force. The Ca
2+
 sensitivity of myofibrils 
within the myocytes was then determined by recording SL in a skinned myocyte while 





C) (Figure  5.1) 




Figure  5.1 Experiments in skinned myocytes. Typical contraction responses of a 
skinned myocyte to Ca2+-containing activating solutions 
5.3 Results 
5.3.1 The effect of esmolol on myofilament sensitivity to calcium in intact 
myocytes  
The relationship between sarcomere shortening and the Ca
2+ 
transient amplitude in 
intact myocytes, determined by varying extracellular [Ca
2+
], was compared with the 
SS/Catr  relationship determined during the negative inotropic effect of esmolol (Figure 
 5.2). Assuming that the negative inotropic effect of reducing extracellular [Ca
2+
] results 
only from the fall of the Ca
2+ 
transient, any difference between these shortening–[Ca2+] 
relationships would indicate an additional action of esmolol (i.e. on the myofibrils 
directly). However, as Figure  5.2 illustrates, the data point plotted from Catr /SS 
relationship generated by reducing extracellular [Ca
2+
] fell over the data points of this 
relationship generated by superfusion with esmolol. Findings were observed in four 
other myocytes we slightly harder to interpret due to the lack of intermediate data points 
generated by esmolol but again there was no suggestion that esmolol had any additional 
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data points from esmolol superfusion would have shifted more to the right (Figure  5.2. 
Therefore we can conclude that much of the negative inotropic effect of esmolol may be 




Figure  5.2 Effect of esmolol (0.3mM/L) on myofilament Ca
+2
sensitivity. Experiment in 
intact myocytes. Results recorded from each contraction in a typical myocyte after 
decreasing the extracellular [Ca
2+
] from 1 to 0.3 mM/L or adding 0.3 mM/L esmolol 
(n=5/group) 
 
5.3.2 The Effect of esmolol on the myofilament sensitivity to calcium in the 
skinned myocytes  
We, next, used skinned myocytes to establish whether esmolol has a direct effect on the 
myofilaments, without any contribution from other cellular organelles. We found that 
adding esmolol (0.3 mM/L) to relaxing and activating solutions had no direct effect on 
the Ca
2+
 sensitivity of myofibrils in the skinned myocytes (Figure  5.3). To examine 
whether esmolol might instead alter myofibrillar Ca
2+
 sensitivity by post-translational 























CHAPTER 5: RESULTS 3 
111 
Figure  5.3 Experiments in skinned myocytes: The effect of superfusing the 
myofilaments with activating solutions with and without esmolol (n=9/group) 
 
10 minutes and then skinned the myocytes. Comparison with a time-matched, control 
group of myocytes (i.e. not treated with esmolol before skinning) showed that 
pretreatment of the myocytes with esmolol before skinning did not alter the 
myofilaments’ contractile response to Ca2+ (Figure  5.4). Thus, esmolol did not appear to 
alter myofibrillar Ca
2+
 sensitivity, suggesting that all of esmolol’s inhibitory action 
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Figure  5.4: Experiments in skinned myocytes. The effect of pre-treating the myocytes 
with esmolol before skinning vs. control group. n=6/group (B). 
 
5.4 Discussion 
Failing myocardium is known by its deficiency in handling calcium (Lee and 
Terracciano 2010). Meanwhile, β-blockers (e.g. bisoprolol) were shown to have an 
effect on the myofilament remodelling in heart failure patients (Hall et al. 1995; Bristow 
2000). Bisoprolol was, also, shown to improve myofilament sensitivity in the intact 
myocardium following MI in pigs on long term pre-ischaemic treatment (Duncker et al. 
2009). However, there is no previous evidence, which shows that adrenergic receptor 
blockers can directly inhibit myofilament sensitivity to calcium. Our observation that 
contraction tends to be inhibited more than the Ca
2+
 transient (Figures 3.7 and 3.8), 
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production is a non-linear function of intracellular [Ca
2+
], such that small changes in 
[Ca
2+
] translate into larger changes in contraction. On the other hand our pilot data, 
which was in a single myocyte were not reproducible. Therefore, these studies do not 
support the desensitising mechanism to explain the negative inotropic effect of esmolol. 
In the previous chapter, esmolol caused significant reduction in both, contraction and 
the Ca
2+
 transient in myocytes with inactive SR (Figure  4.1 Figure  4.2), which suggests 
that a direct effect of esmolol on the SR plays little or no part in its negative inotropic 
action. In these SR-inhibited myocytes, the Ca
2+
 transient is largely due to Ca
2+
 entry 
via the L-type calcium channel, since Ca
2+
 release from the SR is abolished. The large 
reduction in the Ca
2+
 transient under these conditions therefore suggested that a major 
action of esmolol was likely to be via inhibiting Ca
2+
 entry into the cell via the L-type 
Ca
2+
 -channels. Studies in the following chapter examine the effect of esmolol on the 
activity of the L-type calcium channels. 
5.5 Summary and Key Findings 
Alerting the sensitivity of the myofilaments to calcium was suggested as one of the 
mechanism in the pilot data. However, we demonstrated that the relationship of calcium 
and the sarcomere length was similar in the intact myocytes perfused with decreasing 
extracellular calcium and the esmolol-treated. We then explored this possible 
mechanism in the skinned myocytes and demonstrated that the myofilament sensitivity 
to calcium was not altered by either pre-treating the myocytes with esmolol or adding 
esmolol to the activation solution compared with the control group. 
.
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CHAPTER 6. RESULTS 4: THE EFFECT OF ESMOLOL 
ON CALCIUM CURRENTS 
 
6.1 Introduction 
So far, we demonstrated that the negative inotropic effect of esmolol in isolated 
myocytes is independent from any β-blocking, and that the inhibition of contraction 
seems to be mainly due to the inhibition of the Catr (Chapter 3). This proved that the 
profound negative inotropic effect observed in the clinical studies is different from the 
β-blocking effect assumed by Scorsin (Scorsin et al. 2003), Melhorn (Mehlhorn et al. 
1999) and others (Kuhn-Regnier et al. 1999; Kuhn-Regnier et al. 2002). We have also 
excluded any possible involvement of the SR in this effect (Chapter 4) and despite some 
provisional evidence the possibility of any desensitisation to the myofilaments by 
esmolol was excluded using intact and skinned myocytes (Chapter 5). One mechanism, 
which might also explain the decline in Catr by esmolol is that esmolol could have had a 
chelating effect on extracellular ionised calcium, resulting in a reduction in the ionised 
calcium availability and consequently reducing both calcium transient and the force of 
contraction. However, measurement of the ionised calcium concentration was found to 
be comparable in both Tyrode alone and the Tyrode +esmolol solutions. Therefore, the 
effect of esmolol should be through the cellular targets that handle the calcium transient 
and as explained previously esmolol is likely to have inhibited the entry of Ca
2+
 during 
stimulation via the L-type calcium channels. This effect was observed by a cardiac 
surgeon while performing an operation on a beating heart (Arlock et al. 2005). The 
author used esmolol to slightly slow the heart rate in order to be able to operate on the 
heart while beating in what is known as off-pump surgery. This resulted in an observed 
decrease inotropic function and sharp drop in blood pressure, which led his team to 
hypothesise that esmolol had a “direct negative inotropic effect on the myocardium”. 
Steen and colleagues performed limited animal experiment in guinea pigs and pigs heart 
(Arlock et al. 2005); they measured the contraction of the paced ventricular trabecular 
muscle and the action potential after superfusion of esmolol (110 µM) and observed a 
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drop in the plateau phase of the action potential and the force of contraction. Moreover, 
they demonstrated a drop in ICa,L in a single guinea pig myocyte patch clamping 
experiment (Arlock et al. 2005). These findings support the earlier hypothesis that the 
negative effect of esmolol on the calcium transient is by blocking the L-type calcium 
channels. This chapter aims to study the effect of esmolol on the L-type calcium 
channels in order confirm this hypothesis using the ruptured patch clamping technique.  
6.2 Methods 
Rat ventricular myocytes were isolated according to the method described in Section 
 2.3.1. A drop of the myocyte suspension was mounted in the perfusion chamber and the 
myocytes were allowed to settle on the glass bottom of the chamber for a minute. The 
myocytes were subsequently superfused with Tyrode solution. A hydraulic 
micromanipulator (MO-102, Narishige) was used to position the suction glass 
electrodes. The glass electrodes were manufactured from a pulled glass pipette filled 
with the appropriate internal solution and the resistance was measured while the tip is 
immersed in the bath solution. Pipettes with resistance between 1.5 and 3 MΩ were 
used to ensure appropriate tip diameter. A tight seal is formed between the tip of the 
pipette and the surface of the myocyte using the micromanipulators under X40 
microscope objective lens. Seal resistance of greater than 1 GΩ was achieved by 
applying negative pressure (30-60 cm/H2O). The patch membrane was then ruptured by 
a brief period of stronger suction. When a successful rupture was achieved with an 
access resistance less than 6 MΩ the ICa,L  current is measured while the cell is being 
superfused with Tyrode solution for the control measurement and the washout or with 
Tyrode + esmolol at the desired concentration.  
ICa,L  was measured during superfusion with Tyrode’s solution at 34
o 
C. Currents were 
sampled at 10 kHz and filtered at 5 kHz. pCLAMP 10 software (Axon Instruments) was 
used for the acquisition and analysis of currents. In order to be able to record the ICa,L, 
the very large current generated by the fast Na
+
 channels was inactivated using a step 
from -70 mV to -40 mV and K
+




 in the 
internal solution. ICa,L was elicited by a step depolarisation
 
from -40 mV to voltages in 
the range -30 mV to +50 mV. The calcium current depicted in Figure  6.1 is the 
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negatively charged current required by the system to maintain the desired holding 
potential of the cell membrane. This current starts immediately after shifting the 
membrane potential and peaks around 25 ms. Subsequently it slowly decays when the 
inward calcium influx through the activated L-type calcium channels subsides, which 
could take as long as 150 to 200 ms. The size of this is current measured from the peak 
of this inward current to the steady state current after 200 ms. This method has been 
used by many authors as a well established method of measuring the ICa,L  (Liu and 
Kennedy 1998). As expected, this current was maximal at 0 to -10 mV holding 
potential. The concentration-response relationship was studied by superfusing the 
myocytes with Tyrode with increasing esmolol concentrations between 0.1 to 3 mM 
consecutively with 3 minutes superfusion time for each concentration. Thereafter, 
esmolol was washed out with Tyrode and ICa,L  was measured after 5 minutes to insure 
that the effect of esmolol is reversible. The effect of esmolol on the size of ICa,L was 
normalised to the value before treatment as the control for each holding voltage. The 
sigmoid dose response curve was constructed using the effect of esmolol on ICa,L at  
-10mV as it was resulted in maximum ICa,L, the effect was presented in % of control 
value. Subsequently I/V relationship was studied in order to detect any possible effect of 
esmolol on the maximum activation of ICa,L   in relation to the membrane potential. 




Figure  6.1 Typical recording of the calcium current demonstrating the method in 
calculating ICa,L    
6.3 Results 
6.3.1 Esmolol dose response curve on ICa,L    
By treating the myocytes with stepping up concentrations of esmolol, it was found to 
have a dose dependent inhibitory effect on the ICa,L. The concentration-response 
relationship of this inhibitory effect on ICa,L was studied by superfusing each myocyte 
with the increasing esmolol concentrations of 0.1, 0.3, 1.0 and 3.0 mM consecutively. 
At -10 mV, an esmolol concentration of 0.1 mM inhibited the ICa,L  by about 20%, while 
3 mM almost abolished ICa,L. This effect was partially reversible 5 minutes after 
washing out the drug. Figure  6.2 shows a typical recording of a cell demonstrating the 
inhibitory effect on ICa,L. The concentration-response relationship curve was then 
constructed after normalising the effect of esmolol to control for each myocytes at -10 
mV as shown in Figure  6.3. The mean IC50 in 5 myocytes was 0.45 ± 0.05 mM/L (Hill 
coefficient = 0.99 ± 0.18) 
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Figure  6.2: Typical recording of the L-type calcium channel (cell No. 1) current using 
multiple step depolarisation to a voltage range between -40 and +50 mV, A-control 
recording , B- treatment with esmolol (1 mM), C- treatment with esmolol (3 mM), D- 
calcium current after esmolol washout.   
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Figure  6.3: Concentration-response curve of esmolol inhibition on ICa,L with example 
ICa,L trace from cell No. 1 (inset) to compare the effect of esmolol (1 mM) with control 
and washout at -10 mV. 
6.3.2 The voltage dependency of the effect of esmolol 
Superfusing each myocyte with esmolol decreased the magnitude of ICa,L without 
shifting the peak of the I-V curve (-10 mV) and at 3 mM esmolol, ICa,L was nearly 
abolished. Figure  6.4 demonstrates that the inhibitory effect of esmolol on ICa,L  was 
equal at all voltages in all the myocytes included, indicating that ICa,L  block by esmolol 
was not voltage-dependent. After normalising this effect to the percentage of control 
current in order to offset to the size of the cell and the size of the currents at different 
voltages, esmolol indeed seems to have inhibited ICa,L  equally in all voltages (Figure 
 6.5) and therefore this inhibitory effect is clearly not voltage-dependent. 
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Cell No. 1 Cell No. 2 
Cell No. 3 Cell No. 4 
Cell No. 5 
Figure  6.4: The effect of esmolol on the 
L-type calcium current in 5 cells used
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6.4 Discussion 
These studies have confirmed that inhibition of the Catr by esmolol in isolated myocytes 
(Chapter 3) have been mainly by inhibition of the L-type calcium channels. This would 
have resulted in the negative inotropic effect in both the isolated myocytes, and in 
the Langendorff perfused rat heart of Bessho’s study (Bessho and Chambers 2001). 
This novel effect is not widely accepted as it has always been assumed that any 
cardioplegic effect is achieved by β-blockade (Mehlhorn et al. 1999). It was only 
recently that a limited observational experiment (published shortly after starting this 
PhD  project  ) showed a reduction in ICa,L in pig and guinea-pig  myocytes  with  110 
M esmolol (Arlock et al. 2005). These studies were conducted after a profound
negative inotropic effect of esmolol was observed while performing off-pump coronary 
bypass surgery on a patient. Arlock and colleagues using patch clamping techniques that 
were slightly different to our studies (they used the same method to inactivate the fast 
sodium current by stepping up to -40 mV initially and then they stepped straight away 
to 0 mV to activate and measure ICa,L.), they found that esmolol at 110 M reduced ICa,L 
to 72% of control. Our findings in the rat myocytes were generally in line with those of 
Arlock’s; we found that 100 M esmolol resulted in a reduction of ICa,L of 78 ± 4.7% at 
0 mV. 
At 1mM esmolol did not abolish ICa,L  totally; ICa,L was inhibited to 34% of control in 
the isolated myocytes. Bessho and colleagues (Bessho and Chambers 2001) 
demonstrated that 1 mM esmolol induced complete ventricular arrest. Therefore, while 
the negative inotropic effect of esmolol can be sufficiently explained by the inhibition 
of ICa,L , the total arrest in the Langendorff hearts is still difficult to clearly understand. 
This poses the question of whether blocking the L-type calcium channels can entirely 
explain the arresting effect of esmolol in isolated hearts knowing that esmolol at 1 mM 
failed to totally inhibit the ICa,L but yet was able to arrest the heart. In order to answer 
this question it is important to study the effect of esmolol on the fast sodium current, 
which is the first component in the action potential (as shown in Chapter One). 
Blocking the fast Na channel is one of the main mechanisms to induce cardioplegic 
arrest and this is how hyperkalaemic cardioplegia works. We intend, in the following 
chapter, to study the effect of esmolol on the fast Na- channels. 
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6.5 Summary and Key Findings 
Esmolol was shown in this chapter to inhibit the L-type calcium channels using patch-
clamp experiments. This inhibitory effect was dose dependent with an IC50 of 0.45 mM 
and was not voltage dependent 
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CHAPTER 7. RESULTS 5: THE EFFECT OF ESMOLOL 
ON THE FAST SODIUM CURRENTS 
 
7.1 Introduction 
Most non-selective β-blockers are known to have a Na-channel blocking effect at high 
doses and propranolol was proven to be one those agents (Ahrens-Nicklas et al. 2009). 
Despite being a selective β-blocker, esmolol was also shown to have such an effect at 
high doses. Deng and colleagues (Deng et al. 2006) demonstrated, using patch clamping 
studies that esmolol inhibits the fast sodium current (INa ) in isolated rat ventricular 
myocytes. This mechanism could explain the observation in Section  3.3.1, where the 
threshold of myocyte excitation was increased with esmolol treatment. On the other 
hand, blocking the sodium channels can explain the negative inotropic effect of esmolol 
(Honerjager et al. 1986), possibly, by a reduction of intracellular [Na
+
] and thereby, 




 exchanger, which would 
result in less releasable calcium stored in the SR. This effect requires a functioning SR 
and would be lost in the experiment in Section  4.3.1 where the SR was blocked. 
Esmolol however maintained its negative inotropic effect in the blocked SR, which does 
not support this effect entirely. Meanwhile, blocking the L-type calcium channels by 
esmolol (see previous chapter) can explain the negative inotropic effect of esmolol by 
reducing the intracellular calcium and therefore reducing the calcium-induced calcium- 
release (as explained in Section  1.5.5). However, it does not explain entirely the 
mechanism of arrest (as discussed in Section  6.4) and studying the effect of esmolol on 
the fast Na channels seems to be essential as the main trigger for the action potential in 
order to fully understand the arresting effect. Interestingly, Na channels are of great 
importance in cardioplegic arrest as the arrest induced by blocking the Na channels 
directly without shifting the membrane potential is expected to be polarised arrest, 
which could block the detrimental Na window current, which can be potentially 
beneficial compared to hyperkalaemic depolarised arrest as explained in detail 
previously (Sections  1.7.1.2). 
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The study by Deng and colleagues (Deng et al. 2006) demonstrating that esmolol 
inhibits fast sodium channels were conducted in isolated rat ventricular myocytes using 
patch clamp techniques; starting from a holding potential of -120 mV to achieve 
maximum activation of the channels, an inhibitory effect with IC50 of around 75 µM 
was demonstrated. In this chapter, we study the difference between INa generated from a 
holding potential of -120 mV and a more physiological resting membrane potential of -
90 mV. We also looked at the concentration-response relationship and the voltage 
dependence of esmolol inhibition to INa from holding potentials of -90 mV. 
7.2 Methods 
Measuring INa current was slightly harder to obtain than ICa,L due to the easy distruption 
of the seal and the detrimental effect of the slightest leak in the seal on the cell and the 
current. I was assisted during these experiments by Dr. McLatchie who has long 
experience in patch clamping. These studies were conducted according to the method 
described in detail earlier in Sections  2.2.4 and  2.4. In brief, rat ventricular myocytes 
isolated according to the method mentioned in Section  2.3.1. A drop of the myocyte 
suspension was mounted in the perfusion chamber and the myocytes were allowed to 
settle on the glass bottom of the chamber for a few minutes. The myocytes were 
subsequently superfused with Tyrode solution. The electrodes were made from heat 
pulled glass pipette and filled with the Na
+
 patch clamping internal solution (Figure 
 2.8). The electrode resistance was measured with the tip immersed in the bath solution. 
The pipette of resistance between 1.5 and 3 MΩ were used to ensure appropriate tip 
diameter. A hydraulic micromanipulator (MO-102, Narishige) was used to position the 
suction glass electrodes. A tight seal is formed between the tip of the pipette and the 
surface of the myocyte using the micromanipulators under x40 microscope objective l. 
Seal resistance of greater than 1 GΩ was achieved by applying negative pressure (30-60 
cm/H2O). The patch membrane was then ruptured by a brief period of stronger suction. 
If an access resistance less than 6 MΩ was achieved, the Tyrode solution was switched 
to the external solution in the INa experiments (Figure  2.8). The external solution was 
then superfused at 23
o
C only because it was not possible to maintain consistent seals for 
the length of the experiment at a more physiological temperature of 34
o
C. Currents were 
sampled at 10 kHz and filtered at 5 kHz. pCLAMP 10 software (Axon Instruments) was 
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used for the acquisition and analysis of currents. After a short period of stability the INa 
was initially measured from a holding potential of -120 mV and elicited by multiple 
steps to membrane potentials between -80m to +10mV. Then, this measurement was 
repeated by stepping from a more physiological resting membrane potential (-90 mV) 
using the same steps to establish the I/V relationship for both holding potentials. An 
attempt to measure INa by stepping from a holding membrane potential of -80mV did 
not generate a measurable current. The INa was the negative deflection immediately after 
stepping up and it is faster than the ICa,L  measured in the previous chapter as it was 
resolved within 25 ms with a peak around 10 ms (Figure  7.1). The amplitude of this 
current was calculated by measuring the difference between the peak of the curve and 
the flat line 150 ms. later. For some measurements, there was noise in the flat line at 
around 50-60Hz, which was in the shape of regular wave form with an amplitude of no 
more than 50 pA; in order to avoid any error in determining the value of the flat line, the 
curve was averaged over a period of 20 ms and the average value was subtracted from 
the peak. This was normalised to the control when stated or normalised to the 
capacitance of the measured myocyte as the size of the current depends on the size of 
the cell and therefore its capacitance. The concentration-response relationship and rate 
dependency were studied using the holding membrane potential of -90mV. INa was 
activated using a 10 step pulse train from -90mV to -50mV.  
 
Figure  7.1 Example trace of the INa  and the method of calculation   
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7.3 Results 
7.3.1 The I/V relationship study 
In this chapter, our aim was to measure the blocking effect of esmolol on the fast Na-
channels from physiological holding potentials, and compare theses results with the 
findings of Deng and colleagues (Deng et al. 2006) in, which a hyperpolarising holding 
potential of -120 mV was used. The I/V relationship from stepping from either -90mV 
or -120mV was studied using the protocol mentioned above. Four cells (n=4) were 
adequate to demonstrate the I/V relationship variation between the holding potentials  
-90 and -120 mV. The results of individual cells are outlined in detail in Table  7.1. The 
INa currents generated from the holding voltage of -120 mV were, almost 10 times larger 
than the ones generated from the holding voltage of -90 mV after normalising to cell 
capacitance (Figure  7.2). We also found that the peak INa activation was at -60 mV for 
the hyperpolarisation holding voltages, whereas this peak of INa activation had shifted 
slightly towards depolarisation of -40 to -50 mV in the activation step from the holding 
potential of -90 mV (Figure  7.2). 
  





INa Current (pA/pF) 
Cell A Cell B Cell C Cell D 
Stepping from -90 mV 
-70 0.37 0.43 0.22 0.18 
-60 4.54 2.58 2.69 2.10 
-50 10.40 5.29 9.42 7.49 
-40 9.87 4.66 10.10 8.89 
-30 6.89 2.07 7.31 6.57 
-20 3.31 0.11 3.53 3.45 
-10 0.22 0.10 0.18 0.27 
0 0.10 0.12 0.25 0.16 
10 0.04 0.08 0.12 0.22 
Stepping from -120 mV 
-70 4.69 25.63 51.11 3.23 
-60 58.84 74.66 59.23 62.80 
-50 57.96 71.01 53.38 60.35 
-40 51.98 62.21 48.69 53.60 
-30 44.33 51.59 40.21 45.29 
-20 35.83 40.79 32.19 36.22 
-10 27.23 29.84 24.30 27.25 
0 18.25 20.12 16.08 18.29 
10 10.04 10.62 8.27 10.55 
 
Table  7.1 I/V relationship data of individual myocytes demonstrating the difference 
between holding potentials of -90 mV and -120mV 
 
  







Figure  7.2: I/V relationship of INa , A- comparison between stepping from holding 
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7.3.2 The dose-response curve and rate dependency effect of esmolol on INa  
As explained earlier, after stabilisation, baseline INa was measured from holding 
potential of -90 mV stepping to -50 using a 10-pulse train. The myocytes were 
superfused with increasing concentrations of esmolol (from 0.01-1.0 mM). We found 
that, while 0.1 mM esmolol inhibited INa by around 10-20%, the next dose of 0.3 mM 
had inhibition that was close to 90%. To study this part of the steep curve, we included 
another concentration of esmolol at 0.2 mM. We also found that lower concentrations 
(0.01 and 0.03 mM), in some occasions, has slightly increased INa (as shown in Figure 
 7.3, which demonstrates a typical example of INa in a cell superfused with the increasing 
dose of esmolol and then a washout current). It was difficult to be certain that this effect 
was indeed due to the small esmolol dose or whether it was due to variation in the 
measurements. At 1 mM/L, esmolol completely abolished INa, which was reversed 
partially after 3 min of wash out of the drug. There was no difference between the first 
and the tenth pulse at any of the measurements, which excludes any rate dependency in 
the inhibitory effect of esmolol on INa. The INa value was normalised to baseline 
measurement and a dose response curve was constructed for the first and the tenth pulse 
(Figure  7.4). This figure also shows a typical example of the effect of esmolol (0.2 mM) 
on INa. The IC50 values for the first and tenth pulses were not different (0.169 ±0.025 
and 0.162 ± 0.024 mM, respectively; Figure  7.4). Thus, we observed no rate-
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Figure  7.3: Typical recording of INa channel (cell No. 1) using a train of 10 pulses with step 
depolarisation from -90 mV to -50 mV. A-control recording , B- treatment with esmolol 
(0.01 mM), C- esmolol (0.03 mM), D- esmolol (0.1 mM). E- esmolol (0.2 mM), F- esmolol 
(0.3 mM), G- esmolol (1 mM), D- Washout for 3 minutes 
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Figure  7.4: Concentration-response curve of esmolol inhibition on INa with example trace 
INa  to compare the effect of esmolol (0.2 mM) with control and washout at -50 mV (inset) 
7.4 Discussion 
These studies demonstrated that esmolol inhibits INa at lower concentrations than those 
for the inhibition of ICa,L. (with an IC50  0.16 vs. 0.45 mM respectively). Interestingly, 
esmolol at 0.3 mM almost abolished INa. However, we know from our previous studies 
(Bessho and Chambers 2001) that this concentration did not achieve full arrest in the 
Langendorff perfused rat hearts that a higher concentration was required to abolish ICa,L 
as shown in the studies in Chapter  6. This suggests that total inhibition of INa is not 
sufficient to induce arrest in these studies. Sodium channel blockers are known to have a 
negative inotropic effect (Honerjager et al. 1986), possibly because they tend to reduce 
intracellular [Na
+
] and thereby enhance the extrusion of Ca
2+
 from the cell due to the 
increasing the gradient of Na
+
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exchanger; this would result in less releasable Ca
2+
 stored in the SR. It is, therefore, 
possible that an effect of esmolol on the fast Na
+
 channel contributed to the negative 
inotropy in submillimolar doses of esmolol reported in the isolated myocytes studies 
(Chapter 3) and observed by Bessho (Bessho and Chambers 2001) in the rat hearts, as 
well as during cardiac surgery (Arlock et al. 2005). However, it is unlikely that the 
inhibition of INa is the predominant mechanism for negative inotropy and arrest because 
the negative inotropic effect of esmolol was not affected by SR inhibition (Chapter 
4 CHAPTER 4), and the inhibitory effect of selective INa blockers on contraction is 
smaller than on INa (as measured by upstroke velocity of the action potential) 
(Honerjager et al.). We therefore conclude that the inhibition of INa is likely to be a 
contributing factor but that the major mechanism of action for the negative inotropic 
effect of esmolol and arrest is the inhibition of ICa,L.  
 
7.5 Summary and Key Findings 
The effect of esmolol on the fast sodium current was investigated in this chapter using 
patch-clamp experiments. We demonstrated that esmolol inhibited the fast Na current at 
-90 mV in a dose dependent manner. The inhibition was found to be comparable in the 
first and tenth pulse, which concludes that it was not rate dependent inhibition. 
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CHAPTER 8. RESULTS 6: ESMOLOL EFFECT IN THE 
ISOLATED RAT HEART 
 
8.1 Introduction 
The previous studies have demonstrated that esmolol directly inhibits contraction of the 
ventricular myocytes. However, cardiac arrest in the whole heart could be due to either 
direct inhibition of contraction at the level of the myocytes or inhibition of action 
potential at the level of the conduction system. Work from our lab by Bessho and 
colleagues (Bessho and Chambers 2001) has previously demonstrated that whole heart 
perfusion with esmolol only (without any ischaemia) resulted in a dose-dependent 
negative inotropic effect by inhibiting LVDP at lower concentrations (0.3 mM). Further 
increase in esmolol concentration (1 mM) induced full arrest at the level of the 
ventricle, whereas atrial arrest required a higher (3 mM) concentration. (Figure  1.13). 
The dose dependent negative inotropic effect on the ventricle demonstrated in this 
experiment can be explained by the previous findings in Chapters 3 to 7 in the isolated 
myocytes in particular the L-type calcium channel blocking effect in Chapter 6. 
However, the atrio-ventricular dissociation that occurred with esmolol at 1 mM suggests 
an effect on the conduction system; in particular, the AV node. Sodium channel 
blockers have been shown to partially inhibit the pacemaker cells in the AV node 
(Marger et al. 2011). Meanwhile, L-type calcium channel blockers are well known to 
induce complete heart block at the level of the AV node (Regan et al. 2005; Marger et 
al. 2011). It is possible, therefore, that esmolol did indeed induce arrest by blocking the 
AV node through the sodium and L-type calcium channel blocking effect. The other 
possible mechanism can be explained by the poor coronary perfusion to the right atrium 
in the isolated rat heart preparation as the main supply to the right atrium from the SA 
node artery (Yamazaki et al. 2010) can get damaged easily while harvesting the heart. 
This could result in reduction of the bioavailability of esmolol in the atrial tissue and the 
SA node, which explains the need for a higher concentration to induce atrial arrest. The 
aim of this chapter is to investigate the mechanism of arrest in the whole heart and to 
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determine whether, the arrest at the level of the ventricle in Bessho’s work (Bessho and 
Chambers 2001) (Figure  1.13) is either due to direct inhibition of myocytes contraction 
or failure of the pacemaker/ conductive system of the AV node. Furthermore, we aim to 
explain the lack of atrial arrest by esmolol (1 mM) in these experiments, which may be 
explained by the reduction in atrial superfusion.  
 
8.2 Methods 
The isolated of the rat hearts and Langendorff perfusion methodology are explained in 
detail in Sections  2.2.7 and  2.5. In brief, after rapid harvesting of the heart and 
immersion in ice-cold perfusate, it was canulated and perfused with KHB solution 
within 30 to 60 seconds to minimise the length of ischaemia. After removing the left 
atrium, a ventricular balloon was inserted into the left ventricle. The balloon was filled 
with water and the pressure was calibrated to maintain intra-ventricular diastolic 
pressure of 4-8 mmHg. The heart is kept in a water-jacketed glass reservoir covered 
with paraffin film ‘parafilm’ to maintain the temperature, and was then perfused with 
KHB at 37
o
C. For these experiments, an additional cannula was placed over the right 
atrium to superfuse the atrial tissue in order to overcome any potential low perfusion to 
the atrium as explained above. We also inserted a pacing lead on the ventricle to allow 
pacing the heart in order to distinguish between the arrest induced by complete heart 
block or by direct inhibition to the myocardium. A unipolar electrocardiogram (ECG) 
was obtained using an electrode inserted into LV (Figure  8.1). The heart was then 
equilibrated for a 20 minutes stabilisation period. The values were, again, presented as 
percentage of control, measured at the end of the stabilisation period. The sigmoid 
curves were fitted using GraphPad Prism software to the following equation: Y= ymin + 
(ymax-ymin)/(1+(IC50/X)
-n
) where X is the drug concentration, IC50 is the concentration for 
50% of the maximal inhibition, and n is the Hill coefficient. We randomised 5 hearts per 
dose of esmolol and examined doses of 0.03, 0.1, 0.3, 1 and 3 mM. In order to establish 
the mechanism of arrest in the whole heart we designed an experimental protocol, which 
aimed to investigate the mode of action in each part of the rat heart by studying the 
effects of esmolol with and without atrial superfusion or ventricular pacing. 
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Figure  8.1 A photograph of a Langendorff perfused heart with a diagram of the atrial 
superfusion cannula placed above the right atrium (AC). An ECG lead and pacing 
leads and the site of the ventricular balloon insertion. 
LVDP, ventricular heart rate and left ventricular diastolic pressure were measured by 
averaging the ventricular balloon trace over a period of 30 seconds. Atrial heart rate was 
also averaged over 30 seconds from the ECG trace. Coronary flow measured from the 
perfusate collected in the heart chamber over 3 minutes. In the atrial superfusion phase, 
this volume represents a mixture of the atrial superfusate and the coronary flow. 
Therefore, the coronary flow could not be measured correctly using this method and for 
simplicity purposes, we did not measure coronary flow during this phase. The 
experimental perfusion protocol is shown in Figure  8.2 consisted of: 20 min 
stabilisation period with Langendorff retrograde perfusion alone without atrial 
superfusion (control measurement) and then a 3- minute period with additional atrial 
superfusionm a return to coronary perfusion alone (3 min); 3 min LV pacing (360 
b.p.m), then 3 minutes of no pacing. The KHB alone was then replaced with KHB 
containing esmolol (one randomised concentration per heart) for 5 minutes and the 
entire perfusion sequence was repeated with atrial superfusion phase and ventricular 
pacing phase (Figure  8.2). After that the hearts were allowed to recover for 20 minutes 
and LVDP was measured again. 
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Figure  8.2 A diagrammatic representation of the perfusion protocol, (blue bars 
represents KHB perfusion, brown bars represents esmolol perfusion, the green bars 
represents the sampling time). KHB: Krebs Henseleit Buffer, At: atrial, V:ventricular, 
Esmolol: KHB+ esmolol. 
8.3 Results 
8.3.1 Validating the protocol during KHB perfusion 
We initially needed to establish that the protocol preceding the esmolol perfusion did 
not influence LVDP or heart rate. This was important in order to ensure the protocol did 
not alter any esmolol responses and to determine the control point during the pre-
esmolol perfusion. LVDP and heart rate remained stable with no significant changes 
throughout the KHB perfusion period with the exception of heart rate during the pacing 
period at 360 bpm (Figure  8.3). Similarly, the coronary flow rate remained stable 














































































































Figure  8.3 The change in LVDP (left) and heart rate (right) during KHB perfusion for 
all the hearts (n=25)  
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8.3.2 The dose-response relationship of esmolol with or without atrial 
superfusion 
The heart rate during KHB perfusion did not change during atrial superfusion; heart rate 
was 289 ± 13 bpm during KHB perfusion alone vs. 290 ± 11 bpm during KHB with 
atrial superfusion. Langendorff perfusion with 1 mM esmolol drop the atrial rate; in 
contrast, atrial superfusion resulted in 2 hearts achieving full atrial arrest electrically and 
a substantial decrease in the atrial rate of the other 3 hearts to giving a mean heart rate 
































































Figure  8.4 Atrial rate variation in the esmolol (1 mM) hearts (n=5) demonstrating the 
effect of esmolol on atrial rate with Langendorff perfusion only and a more profound 
effect with atrial superfusion. (yellow bars are the Mean, error bars are SEM) 
While 0.03 mM of esmolol had negligible effect on heart rate with and without atrial 
superfusion it inhibited LVDP significantly to 78±3% of control. Higher sub arresting 
doses (0.1 and 0.3mM) of esmolol have reduced heart rate to 86±2% and 73±6% of 
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control respectively in normal perfusion and 85±3% and 68±5% of control respectively 
with atrial superfusion. The inhibitory effect of these doses on LVDP was more 
profound to 51±4% and 20±6% of control respectively. 1 and 3 mM esmolol induced 
arrest similar to findings by Bessho and colleagues (Bessho and Chambers 2001) 
 
8.3.3 The dose-response curve of esmolol in paced vs. unpaced hearts with 
standard perfusion  
This study was conducted to establish whether the ventricular arrest induced by esmolol 
is caused by an inhibition of the conduction system, in particular the A-V node. In order 
to achieve this, we constructed the dose-response curve of esmolol on LVDP in the 
initial Langendorff perfusion phase normalised to the LVDP measured at stability 
(control). This was then compared to the dose-response curve of esmolol in the paced 
phase normalised to the same period. As expected, heart rate was different between the 
two phases; esmolol concentrations below an arresting threshold dose did not slow heart 
rate during the paced phase, whereas these doses reduced heart rate during the 
spontaneously beating phase (Section  8.3.2). This variation in heart rate, however, did 
not alter the inotropic response and the inhibitory effect on LVDP in the paced phase 
comparative to the unpaced phase. By constructing the average sigmoid curve of this 
dose-response relationship of esmolol on LVDP in the paced versus the unpaced hearts, 
the IC50 values were 0.109 ± 0.014 mM and 0.097 ± 0.013 mM, respectively with the 
Hill coefficient values being 1.3±0.19 and 1.3±0.19, respectively (Figure  8.5). At 1 mM 
esmolol, pacing the heart failed to generate any contraction, which confirms that 
esmolol inhibited the contraction directly at the level of the myocardium rather that the 
conduction system. 
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Figure  8.5 Concentration–response curves for esmolol in Langendorff-perfused 
hearts demonstrating the effect on LVDP in ventricular paced (360 b.p.m.) vs. 
unpaced (280±50 b.p.m.) hearts 
 
8.3.4 Esmolol dose-dependent recovery studies 
The esmolol concentrations used to induce heart arrest are very high compared with the 
normal plasma concentrations of   10-100 µM (Adamson et al. 2006) when esmolol is 
used clinically as a β-blocking agent due to its hypotensive ability. Therefore, it was 
important to ensure that, at these high concentrations, esmolol does not have a long 
lasting-detrimental effect on the heart. Equally, we needed to establish the optimal dose 
used to induce effective arrest, and at the same time ensuring that this effect is 
reversible as soon as possible after esmolol is washed out. In order to do this, hearts 
were perfused for an additional 15 minutes with KHB alone after the protocol shown in 
Figure  8.2, LVDP, and heart rate were measured at 0, 1, 3, 5, 10, and 15 minutes and 
recovery is shown in Figure  8.6 and Figure  8.7. The reversibility of the negative 
inotropic effect of esmolol is dose-dependent, with 0.3 mM appearing to demonstrate a 
rapid reversibility very instant reversibility with an improvement in LVDP compared to 
control. A concentration of 1 mM esmolol also showed complete recovery of LVDP, 
but it was significantly slower with partial recovery in heart rate.  































Figure  8.6 Washout of the effect of esmolol on LVDP. Time zero represents LVDP at 
the end of the perfusion with esmolol, before washout with KHB. Data are normalised 


































Figure  8.7 Washout of the effect of esmolol on heart rate. Data are normalised to the 




The studies described in previous chapters demonstrated that esmolol exhibited negative 
inotropic effects at the level of the myocytes. In addition, Bessho and colleagues 
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(Bessho and Chambers 2001) have showed that 1mM esmolol resulted in an atrio-
ventricular dissociation, which may have been as a direct block of the conduction 
system, in particular the AV node. This mechanism is very feasible, as sodium and 
calcium channel blockers have been shown to have inhibitory effect on the AV node 
(Regan et al. 2005; Marger et al. 2011). It was important to confirm that arrest in the 
whole heart was not limited solely to inhibition of conduction without direct inhibition 
of myocardial contraction, in order to evaluate the suitability of esmolol arrest in cardiac 
surgery. It is not feasible to rely on cardioplegic potential for an agent, which has 
residual excitability of the myocardium for many practical reasons; during surgery, it is 
possible that the heart becomes excitable by directly handling the ventricles during 
surgery, which could result in contraction while working on the heart. This could be 
potentially dangerous during critical surgical manoeuvres or even by exposing the heart 
to contraction during ischaemia as it increases energy consumptions. Another clinical 
scenario where such arrest is not feasible during surgery is in patients with an internal 
pacemaker, which might result in failure to induce arrest altogether. The findings 
Section ( 8.3.2) reproduced those of Bessho and colleagues’ (Bessho and Chambers 
2001) demonstrating the negative inotropic effect of esmolol on the ventricle by 
reducing the LVDP significantly and inducing full ventricular arrest at 1 mM. We also 
reproduced the lack of atrial arrest electrically using 1 mM in the standard Langendorff 
perfusion method. Moreover, we demonstrated that by superfusing the atrium with 
esmolol we managed to increase the arresting effect and the negative chronotropic effect 
of esmolol on the atrium. After normalising the LVDP and heart rate to the control 
measurements following the stabilisation period we constructed a dose response 
relationship in the same manner as in Bessho’s study (Bessho and Chambers 2001),  
which is depicted in Figure  1.13 in the First chapter and is shown again in Figure  8.8 
alongside the data from this study. The effect of atrial superfusion on atrial rate was 
found to be statistically significant in the 1 mM group using paired t-test (P<0.05). At 
0.3 mM atrial superfusion further decrease the heart rate including the ventricular rate 
without inducing ventricular arrest, which explains the difference between the average 
in atrial rate during atrial superfusion, which is in fact the heart rate and ventricular rate 
during Langendorff perfusion alone in this dose group in Figure  8.8.   
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Figure  8.8 Concentration-response curves for the effect of esmolol comparing our 
findings (left panel) with Bessho’s published results (right panel). Left showing effect 
on LVDP (   ), ventricular rate (    ), atrial rate (   ), and the atrial rate during additional 
atrial superfusion (    ). Right panel is duplicate of Figure  1.13 taken from Bessho and 
colleagues (Bessho and Chambers 2001) showing LVDP (    ) ventricular rate (   ) and 
atrial rate (  ). 
This study clearly does not exclude the inhibitory effect of esmolol on the conduction 
system in general and the AV node in particular. It does, however, confirm that esmolol 
arrest in the whole heart is not caused or limited by this mechanism and that the direct 
inhibitory effect on the isolated myocytes shown in earlier chapters is the main arresting 
mechanism. It is, therefore, appropriate to use as a cardioplegic arrest in heart surgery 
for the reasons mentioned above.  
The washout studies later have confirmed that the reversibility of esmolol’s effect on 
LVDP and heart rate is dose dependent; while 1 mM offered robust and effective arrest, 
the recovery was partial in heart rate and slow in LVDP recovery despite being 
complete after 15 minutes; it was slower than in 0.3 mM. On the other hand 0.3 mM 
arrest was not consistent. This has suggested the question whether inducing arrest was 
the main important factor in determining the reversibility of esmolol in the 0.3 mM 
group. By performing subgroup analysis onto 0.3 mM treated hearts we found that the 2 
arrested heart average LVDP recovery was very close to the three unarrested hearts. 
This excludes the possibility that recovery from esmolol treatment at these doses is 
dependent on whether arrest has been induced or not.  
(mM) 
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In summary, this study demonstrated that esmolol can offer a practical cardioplegic 
arrest by direct inhibition of the myocardium, which makes it appropriate to be used in 
cardiac surgery. There is a concentration window where esmolol can provide effective 
arrest but can still show efficient and rapid reversibility during reperfusion and the 
window appears to be between 0.3 mM and 1 mM in the rat hearts with this crystalloid 
preparation. Further studies are required to establish whether these data will translate 
into larger animal hearts and in human studies.  
8.5 Summary and Key Findings 
The effect of esmolol was studied in the Langendorff perfused rat hearts in order to 
establish whether the arrest in the heart was due to the inhibition of the conduction 
system only or whether esmolol’s inhibitory effect was at the level of the myocardium. 
We demonstrated that esmolol induced ventricular arrest at 1mM. Meanwhile atrial 
arrest required 3mM of esmolol. These findings were in line of Bessho‘s work (Bessho 
and Chambers 2001). We, then demonstrated that superfusing the atrium has resulted in 
inducing atrial arrest in some of the hearts at 1 mM. Equally, pacing the ventricle during 
esmolol arrest did not generate contraction. 
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9.1 Esmolol’s mechanism of arrest 
Since the development of propranolol as a β-blocker in the 1960’s, it has been shown to 
have many indications. These include myocardial protection against ischaemic heart 
(Mason et al. 1969), treating hypertension (Waal 1966), atrial arrhythmias (Harrison et 
al. 1965) and hyperthyroidism (Howitt and Rowlands 1966). This resulted in huge 
development of more selective and non-selective β-blockers. However, the development 
of the parenteral short acting-β-blocker esmolol has shifted the target patients from 
chronic therapeutic use to critically ill patients (Zaroslinski et al. 1982), mainly to 
control heart rate and titrate blood pressure. Shortly after that, its role in mitigating for 
the injury of myocardial infarction in the acute phase was studied (Lange et al. 1983). 
Within a few years it became obvious that esmolol had something to offer in the acute 
setting of myocardial infarction and it was consequently used for the first time by 
Frazier and Sweeny (Sweeney and Frazier 1992) in emergency surgical 
revascularisation using minimal ventricular contraction. It was in the acute setting when 
high doses of esmolol were first used. Since, the main problem with esmolol when 
given at high doses is hypotension, this was less of a problem during cardiac surgery 
with minimal ventricular activity because the patient’s circulation is already supported 
by a ventricular assist device (Sweeney and Frazier 1992) or later by conventional 
cardiopulmonary bypass (Kuhn-Regnier et al. 1999; Scorsin et al. 2003). The negative 
inotropic and chronotropic effects induced by esmolol had always been assumed to be 
due to its β-blocking activity. The minimal ventricular activity reported by Sweeney 
(Sweeney and Frazier 1992) could have been partially explained by its β-blocking effect 
as blocking the β-receptors in patients could have resulted in a small negative inotropic 
and chronotropic effect by blocking the systemic effect of the circulating 
catecholamines. However, in the study by Scorsin and colleagues (Scorsin et al. 2003), 
esmolol was administered directly into the coronary arteries using a bolus of 250 to 300 
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mg over a period of 2 to 3 minutes. One can extrapolate that esmolol concentration 
would have been close to 1 mM, as the coronary flow over this 3 minute- period could 
not have been more than a litre. This resulted in profound bradycardia (30 bpm) and 
negative inotropic effect, which was assumed to be due to the β-blocking effect. Again, 
in this clinical study, esmolol was administered in vivo where there is normally a 
catecholamine background to, which esmolol could have blocked the cardiac response. 
However, the use of such high concentrations and the profound bradycardic response 
does suggest that the mechanism of action of esmolol was beyond blocking the β-
receptors in the heart and could possibly be exerting a direct negative inotropic and 
chronotropic effect. In addition, in vitro studies using Langendorff perfused hearts from 
our lab (Bessho and Chambers 2001; Bessho and Chambers 2002) and others (Ede et al. 
1997) in, which complete cardioplegic arrest was achieved with esmolol as an 
alternative to the conventional cardioplegia could not be explained by blocking the β-
receptor in isolation of background catecholamine circulation. Pilot data from our lab 
using single myocyte confirmed the independence of β-receptors from this effect, and 
also demonstrated a direct negative inotropic effect of esmolol by inhibiting contraction 
and Catr (Figure  1.14). Importantly, it showed the persistence of smaller amplitude of 
Catr with complete inhibition of contraction. One mechanism that could explain this is 
desensitisation to calcium. Another possible mechanism was that esmolol blocks the L-
type calcium channels as has been suggested by Arlock and colleagues (Arlock et al. 
2005) from an observation they made while operating on a patient using off pump 
beating heart surgery where a bolus of esmolol resulted in profound hypotension and 
negative inotropic effect necessitating emergency conversion to cardiopulmonary 
bypass. They studied this effect further by measuring the action potential and observed 
an inhibition in the plateau phase of the action potential, which is dominated by calcium 
entry through the ICa,L  channels. Subsequently, they measured the ICa,L  using patch 
clamping experiments in pig and guinea pig hearts, with results suggesting possible 
inhibition of ICa,L  (Arlock et al. 2005).  
The initial studies ( Chapter 3) aimed to reproduce the findings of the pilot data (as in 
Figure  1.14). We showed that esmolol inhibited contraction in the paced isolated 
myocytes in a dose-dependent manner, and at 1 mM it inhibited contraction. This 
inhibitory effect was not altered with background perfusion of atenolol, which suggests 
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that it is independent from the β-blocking receptors. The calcium transient was also 
inhibited to a lesser extent than the negative inotropic effect. These observations were in 
line with the original myocyte pilot data with the exception of being unable to reproduce 
the persistence in the calcium transient at higher esmolol concentrations (1 mM) when 
complete arrest was achieved. The mechanism of action was therefore proven to be 
independent from the β-receptors, and calcium transient inhibition was shown to be 
instrumental in this negative inotropic effect. Therefore, in subsequent studies in the 
following chapters, we aimed to explore, by exclusion, the possible mechanism or 
mechanisms that can induce such effect. In Chapter 4 , we established that the SR was
independent from this effect by demonstrating the negative inotropic effect of esmolol 
in myocytes pre-treated with an SR blocker. The possibility of myofilament 
desensitisation by esmolol, which was suggested by the pilot data was investigated in 
Chapter 5; in skinned myocytes esmolol did not alter the response to calcium. This was 
tested by pre-treating the myocytes with esmolol before skinning, and in a separate 
experiment when it was added to the activation solution and applied directly to the 
myofilaments after skinning. In a more physiological preparation of intact myocytes, the 
relationship between contraction and extracellular calcium was studied in individual 
myocytes with or without esmolol; again, there was no indication that esmolol had any 
effect on desensitising the myofilament to calcium. After excluding these two 
possibilities, we turned to patch clamping techniques and investigated the effect of 
esmolol on ionic channels in the myocyte membrane. Arlock and colleagues (Arlock et 
al. 2005) have suggested the possibility of inhibiting the ICa,L  current by measuring the 
action potential and recorded inhibition in the calcium phase. In Chapter 6 , the effect of
esmolol on the L-type calcium channels was studied and this demonstrated that esmolol 
inhibited the ICa,L  in a dose-dependent manner. The inhibition of the L-type calcium 
channel would explain the negative inotropic effect, leading to higher doses causing 
contractile failure and therefore the induction of arrest. However, any further influence 
of esmolol on other membrane channels cannot be excluded. One particular target that 
was important to explore is the fast sodium channels; β-blockers were known for their 
local anaesthetic effect at high doses (Smith 1982). Additionally, in a few experiments 
on the paced intact myocytes, it was noticeable that the pacing threshold to induce 
contraction has increased once the 
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myocytes where superfused with esmolol below the arresting doses, and this can be 
explained by a local anaesthetic effect (ie. Na-channel blockade). Therefore, the effect 
of esmolol on the fast sodium channels was examined using the ruptured patch 
clamping technique (described in Chapter 7); we demonstrated that esmolol
inhibited the fast sodium channel current at lower concentrations than those that 
inhibited the L-type calcium current. We also demonstrated that this effect was not rate 
or voltage-dependent. Deng and colleagues (Deng et al. 2006) had presented similar 
results by measuring INa from hyperpolarising holding potentials of -120 mV compared 
to the more physiological holding potential of -90mV used in our experiments. Sodium 
channel blockers are known to have a negative inotropic effect (Honerjager et al. 1986), 
possibly by reducing the intracellular [Na
+
] and subsequently increase the extrusion of 
calcium from the cell via the sodium/calcium exchanger. This could result in less 
releasable calcium stored in the SR. It is, therefore, possible that an effect of esmolol on 
the fast sodium channels contributed to the negative inotropic effect of esmolol by this 
mechanism. However, we demonstrated that the negative inotropic effect of esmolol 
was independent from the SR function, which makes it unlikely for the inhibition of fast 
sodium channels to be the predominant mechanism. As for the arresting effect of 
esmolol in Langendorff- perfused hearts, we demonstrated that, despite significant 
inhibition of INa at 0.3 mM in the isolated myocyte, esmolol failed to arrest the heart at 
these concentrations. This suggests that the action potential at these concentration is still 
being generated with very little or no effect from the Na channels. A possible 
explanation for this could be that the action potential generated using doses between 0.3 
and 1 mM concentrations has been through a Na independent mechanism, which was 
described as the slow action potential where an action potential was generated in paced 
myocytes (Li and Sperelakis 1983). Even this mechanism does not reliably explain the 
arrest (or lack of it) using this range of esmolol in the Langendorff rat hearts without 
considering that the two mechanisms of blocking the sodium and the calcium channels 
are complimentary to each other. Beyond trying to understand the exact mechanism of 
esmolol, this also proposed a question of whether the negative inotropic effect observed 
at submillimolar concentrations without arrest is just a smaller effect of the same 
phenomenon, which eventually leads to a total arrest at higher concentrations, or 
whether the arrest and the negative inotropic effect are two separate phenomena. It is 
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possible that esmolol had induced the negative inotropic effect by targeting the myocyte 
while the arrest was induced by blocking the pacemaker and the conduction system. The 
final results chapter aimed at answering this question by defining the arrest and the 
negative inotropic mechanisms in the Langendorff perfused rat heart. Bessho and 
colleagues (Bessho and Chambers 2001) demonstrated that esmolol (at 1 mM) induced 
ventricular arrest with the persistence of atrial activity (Figure  1.13).  These findings 
suggested that esmolol could have induced arrest in these hearts by inhibiting the 
conduction system only, in particular the AV node. By modifying the Langendorff 
perfusion model through pacing the ventricle and superfusing the atrium separately, we 
demonstrated that contraction was inhibited in the ventricle at the level of the 
myocardium, with arrest not being limited to inhibition of conduction. We also 
demonstrated that the lack of arrest at the level of the atrium is possibly due to the lack 
of perfusion.  
In conclusion, these studies have demonstrated that esmolol has an inhibitory effect on 
the fast Na and the L-type calcium channels along with its known effect as a β-blocker 
in the myocardium. This effect is dependent on the therapeutic concentration as 
demonstrated schematically in Figure  9.1. The concentration response studies have 
shown that the inhibition of the L-type calcium channel requires higher concentrations 
of esmolol than the Na channel blocking effect. These concentrations are closer to the 
concentrations, which induces arrest to the heart. This strongly suggest that, despite the 
theoretical importance of INa  arrest in initiating the action potential, blocking the L-type 
channels was the instrumental mechanism in its negative inotropic effect and most 
importantly, its cardioplegic arrest.  
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Figure  9.1 Schematic diagram presenting the inhibitory effect of esmolol on the 
cellular targets in relation to concentration.  
9.2 Designing future cardioplegic solutions and the potential 
application of esmolol in polarising cardioplegia 
The introduction of this thesis highlighted the limitations of hyperkalaemia-based 
cardioplegia (Section 1.7.1.1), which has remained the gold standard in ischaemic 
myocardial protection its development in the since was developed in the 1970’s; 
elevated extracellular potassium depolarises the membrane potential, which inactivates 
the fast Na
+
 channels and thereby blocks conduction of the myocardial action potential.





demonstrated in Figure  1.10. Despite the long standing attempts to find an alternative to 
hyperkalaemia to overcome its limitations most concepts remained at the experimental 
and lab stage. We previously indentified certain criteria, which should be met in 
designing any cardioplegic solution (Section 1.6.1 1.6.1) and these can be summarised 
by the following; the ability to arrest, to have myocardial protective specifications 
against ischaemia, to be rapidly reversible and to have low toxicity and short half-life. 
We also identified the possible cellular targets and mechanisms in Section  1.7, which 
can or have been targeted to induce cardioplegic arrest. These cellular targets and the 
agents investigated to induce cardioplegic arrest are highlighted in Figure  9.2. In 
Section  1.7 we reviewed a number of pharmacological agents individually, and 
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concluded that most of these agents have never been used beyond animal trials. In 
addition, we concluded that most of these agents would have not met all the criteria 
identified for a suitable cardioplegic solution. Whilst the majority of these agents were 
probably able to induce arrest and offer some myocardial protection, there were some 
concerns about their safety when used in high arresting doses, due to the possibility of 
slow reversibility and possible accumulation in the blood stream with long lasting effect 
beyond the cessation of cardiopulmonary bypass (Fallouh et al. 2009). Table  9.1 
highlights these criteria and indicates the suitability of the various pharmacological 
agents investigated or identified as possible cardioplegic agents.  
Figure  9.2 Schematic demonstrating the cellular targets and different cardioplegic 
agents have been studied clinically and experimentally (modified from Figure  1.3 
Schematic graph explaining the concept of myocardial protection associated with 
cardioplegia in prolonging the period of reversible ischaemia. Figure  1.7) 
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Table  9.1 The efficacy vs. safety profile of potential pharmacological arrest agents for 
cardioplegia (: suitable, X: not suitable, ?: further evidence is required)  
These safety criteria could possibly be a reason why most of these agents were not used 
clinically as an alternative to conventional cardioplegia. As for esmolol, it was shown to 
be able to induce cardiac arrest in diastole (Bessho and Chambers 2001), which makes it 
conceptually suitable to be used as a cardioplegic agent. It was also found to be 
protective against ischaemia/reperfusion injury (Roth and Torok 1991; Roth et al. 
1995), and to be safe and effective as an intermittent cardioplegic agent (at least in in-
vitro isolated rat hearts) (Bessho and Chambers 2001; Bessho and Chambers 2002). As 
esmolol has a short half-life due to breakdown by red cell esterases (Erhardt et al. 
1983), its clearance does not depend on the liver or the kidneys, which might be 
compromised during cardiopulmonary bypass. This makes the effect of esmolol 
significantly reduced before the cessation of cardiopulmonary bypass. It is, therefore, 
not surprising that esmolol was used as an alternative to cardioplegia in clinical trials 
with success and in in-vivo canine trials mentioned above where continuous coronary 
perfusion of esmolol was maintained creating profound bradycardia (minimal 
myocardial contraction) with systemic circulation being supported with 
cardiopulmonary bypass. Despite the fact that conventional complete cardiac arrest was 
not achieved with esmolol in these clinical studies, this application was proven to be a 





 ? ?  ? 
Myocardial 
Protection 
     
Reversibility    X  
Safety X XX  X ? 
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safe and effective alternative to conventional blood cardioplegia (Kuhn-Regnier et al. 
1999; Geissler et al. 2000; Scorsin et al. 2003). It is possible that complete arrest using 
high doses of esmolol might not confer the same protection it offered when it was used 
for minimal ventricular activity, as we have shown (Section  8.3.4) that the best 
reversibility for LDVP after washing out esmolol in the Langendorff hearts was 0.3 mM 
(Figure  8.6); a concentration lower than the arresting effect. This poses the question 
regarding the possibility of achieving arrest by combining another agent, which can 
offer synergistic arresting effect to esmolol at doses below the arresting concentrations 
in order to benefit from the rapid reversibility of lower doses of these agents. The agents 
that are likely to offer such effect are expected to target different cellular targets from 
esmolol and at the same time should be meeting the criteria set above. Therefore, this 
excludes all other sodium and calcium channel blockers and narrows the choice to the 
remaining two mechanisms; potassium channel activation and myofilament 
desensitisation (Figure  9.2). By referring to Table  9.1, one can conclude that adenosine 
looks to be the most suitable agent to combine with esmolol in order to enhance the 
arresting effect of esmolol and possibly other myocardial protective effects. We can also 
argue that the addition of a myofilament desensitiser like BDM could enhance the 
arresting and myocardial protective effect further. However, BDM long-term safety and 
its toxicological burden on patients after weaning the cardiopulmonary bypass has to be 
established as the information on this is very limited in this context. As a conclusion, a 
cardioplegic preparation can therefore be designed with targeting these multiple cellular 
mechanisms without ignoring the criteria highlighted above. 
Interestingly, a cardioplegic preparation, which contains esmolol and adenosine is likely 
to induce an arrest by blocking both sodium and calcium channels and also activating 
the K (Ach) channels in the SA node without depolarising the myocyte membrane. This 
is, therefore, likely to be a polarising cardioplegic preparation, which can be a viable 
alternative to the depolarising St. Thomas’ Hospital cardioplegia.  
The following chapter will explore this principle, and will provide preliminary data for 
future studies in designing a clinically viable polarising cardioplegic solution, which can 
overcome the limitations of the current St. Thomas’ Hospital Cardioplegia. 
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9.3 Limitations of experimental models 
This PhD examines the effect of arrest by esmolol in the rat hearts in physiological 
rather than pathological settings which is usually different in patients coming in cardiac 
surgery. Additionally, patients undergoing cardiac surgery are usually already on a 
variety of cardiac active agents which can be β-blockers, calcium channel blockers 
potassium openers or even Na channel blockers. This could interact with any possible 
effect of esmolol in these hearts. Finally, and as explained earlier in Chapter 1 the rat 
heart blood supply is different from the human by the dual intra and extra-cardiac blood 
supply (Halpern 1957), meanwhile in the Langendorff perfused model the blood supply 
is mainly through the coronary arteries and we assume that there is no regional 
ischaemia is sustained because of that and there is adequate collateral supply between 
the two networks. 
In terms studying the effect of esmolol on the isolated myocytes, these experiments are 
performed in non-physiological conditions and settings; for instance the calcium 
sensitive Fura 2 which was used in Chapters 3 and 4 is known to have a chelating effect 
to calcium which could potentially have an added negative inotropic effect. Meanwhile, 
the patch clamping studies were designed to demonstrate the current in an artificial 
setting like hyperpolarising the cell before activating the Na current, equally many non-
physiological compounds to dilute the cytosol. However, all these methods are well 
established investigation tools which should provide reliable information. 
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CHAPTER 10. RESULTS 7: ESMOLOL ADENOSINE 
CARDIOPLEGIA (PILOT DATA) 
10.1 Introduction 
We have previously demonstrated that 1 mM esmolol can offer cardioplegic arrest 
through blocking the L-type calcium channels and the fast Na-channels. This is likely to 
be polarising arrest as the extracellular K
+
 is not being altered. We also suggested that
esmolol can be a clinically suitable cardioplegic solution (Fallouh and Chambers 2007; 
Fallouh et al. 2009) due to its short half life and its breakdown in the red cells. In 
Section  8.3.4 we demonstrated that the reversibility of esmolol at 0.3 mM was superior 
to the 1 mM concentration presented by quicker and higher LVDP recovery and heart 
rate (Figure  8.6 Figure  8.7). Esmolol at concentrations 0.3 mM, however, did not arrest 
the heart reliably. The possibility of combining esmolol with another agent could be a 
successful strategy to overcome this limitation and offer suitable to be used clinically as 
a cardioplegic solution. After systematic review exploring all agents explored in the 
previous chapter (Section 9.2), adenosine was identified to be a suitable pharmacological 
agent to enhance the arresting and the myocardial protection effects of esmolol at lower 
concentrations, which could offer faster reversibility. We intended in this final chapter 
to evaluate the concept of combining esmolol and adenosine in a polarising cardioplegic 
solution, which aimed to induce arrest by influencing multiple cellular targets. This 
study was performed under my direct supervision by a medical student during the 
summer holiday and intended to assess the combination as a proof of concept in 
designing the future polarising cardioplegia. Similar solution was designed by Dobson 
and colleagues (Dobson and Jones 2004) using a combination of lidocaine and 
adenosine and was shown to be a very effective arresting solution with protection 
superior the current gold standard solution, St. Thomas’ Hospital cardioplegia. However 
esmolol and Lidocaine has one limitation; this solution can be administered in limited 
quantities due to the possibility of lidocaine systemic accumulation and toxicity 
(Corvera et al. 2005; Fallouh and Chambers 2007). This limitation is not shared by 
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esmolol and adenosine combination as explained earlier (Section 9.2). This experiment 
assesses the effectiveness of the arrest and the protective specification of an esmolol and 
adenosine combination compared with the lidocaine and adenosine combination and 
with the conventional St. Thomas’ Hospital Cardioplegia. 
10.2 Methodology 
10.2.1 Langendorff perfusion 
The isolation of the rat hearts and the Langendorff perfusion methodology is explained 
in details in Sections  2.2.7 and  2.5. In brief, after rapidly excising the heart it was 
attached to the Langendorff perfusion system and perfused with KHB solution perfused 
within 30 to 60 seconds to reduce the length of ischaemia. After removing the left 
atrium, the ventricular balloon was inserted through into the left ventricle. The heart is 
maintained in a water-jacketed glass reservoir covered with paraffin film ‘parafilm’ to 
maintain the temperature with a thermometer probe in the heart chamber to ensure the 
desired temperature is maintained. The heart was then perfused with KHB perfusion at 
37
o
C at pressure of 100 cm of water. An intra ventricular balloon was adjusted by filling
the balloon to achieve an end-diastolic pressure of around 4-6 mmHg. A surface ECG 
lead was attached to the surface of the ventricle to record a unipolar recording and was 
left to stabilise for 20 minutes. The hearts were then randomised to the desired treatment 
and the desired temperature and the perfusion pressure for all treatments was always 
maintained at 100 cm of water. Values were, again, presented as mean ± standard error 
of mean (SEM) after normalising to control, which was measured after the stabilisation 
period unless stated otherwise. Esmolol, adenosine and lidocaine were prepared by 
adding the desired concentration to the KHB solutions. 
10.2.2 Dose combination and ischaemic protocol 
In this study, our aim to identify the combination doses that deliver a reliable and timely 
arrest with a target esmolol concentration below 1 mM and as close to 0.3 mM as 
possible, based on the washout data presented in Section  8.3.4. Meanwhile, studies from 
Dobson and colleagues (Dobson and Jones 2004) have demonstrated that an adenosine 
dose range around 0.2 mM would offer maximum protection and effective arrest as an 
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additive to the fast sodium channel blocker, lidocaine. Preliminary studies on a single 
heart concluded that esmolol at 0.3 mM and adenosine at 1 mM failed to arrest the 
heart; it became clear that increasing the concentration of esmolol would be required in 
order to achieve an effective arrest. We opted to use 0.6 mM of esmolol and run a dose 
response study to assess the time to achieve arrest when combined with the adenosine at 
a range of the following doses; 0.125, 0.25, 0.5 and 1 mM. Studies were conducted 
using 4 hearts; each heart was randomised to the 4 groups of adenosine concentrations 
combined with esmolol (0.6 mM). The times to full arrest were 70, 53, 50 and 38 
seconds, respectively. We chose the combination of esmolol 0.6 mM and adenosine 
0.25 mM as the optimal concentration to conduct the following preliminary studies to 
assess the suitability and effectiveness of the combination as a cardioplegic solution.  
St. Thomas’ Hospital Cardioplegia (STH2) is remained the gold standard whereas 
lidocaine (0.6mM) and adenosine (0.2mM) cardioplegia (LAC) was shown to offer 
superior protection over STH2 (Dobson and Jones 2004). We aimed to design an 
ischaemic protocol, which has the best chance to demonstrate any possible superiority 
of esmolol and adenosine combination as cardioplegia (EAC) over STH2 and LAC, and 
can translate to the clinical environment. Therefore, we opted to mimic the situation 
during complex operations where long periods of ischaemia can be unavoidable. This 
has become the trend in the way the profile of cardiac surgery recently as patients are 
becoming older and sicker with multiple pathology (Parissis 2011) and, hence, better 
myocardial protection is more important than ever in these situations. In order to 
address this need, we used a prolonged period of ischaemia (four hours) with multiple 
cardioplegic infusion (3 minutes) at intervals of 30 minutes instead of the classical 20 
minute-interval. This is, again, one of the situations that surgeons are facing more 
frequently when dealing with multiple valves or major aortic surgery, when 
occasionally, it is not technically feasible to be able to give cardioplegia religiously ever 
20 minutes as this could lead in interruption of the surgical flow and results in overall 
further delay in the ischaemic time. Equally, the general practice in such procedures is 
to use topical cooling on the heart during ischaemia and to use cold cardioplegia 
(Robinson et al. 1995). Therefore, we used room temperature cardioplegia in a 
crystalloid preparation and the heart was maintained at room temperature during 
ischaemia. After the stabilisation period 18 hearts were randomised into treatment with 
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either STH2, EAC or LAC. 6 hearts in each group (n=6). After 4 hours ischaemia with 
multiple cardioplegic administration at 30 minutes interval the hearts were perfused 
with KHB solution. Time to arrest, EDP during ischaemia (ischaemic contracture), heart 
rate recovery and LVDP recovery were recorded. Statistical analysis is performed by 
using 2 way ANOVA and Bonferroni post-hoc test. 
10.3 Results 
10.3.1 Esmolol adenosine cardioplegia vs. lidocaine adenosine cardioplegia 
and STH2 





 seconds for EAC, STH2 and LAC respectively (
*
 P<0.001).
Ischaemic contracture was measured by recording the maximum intra-ventricular 
pressure recorded during the ischaemic period. The maximum EDP values were The 
highest contraction was seen in the STH2 group and these values were 9.8±1.4, 
18.3±4.5 and 76.3±16.8
*
 mmHg for EAC, LAC and STH2 respectively found to be also
significantly different between the three groups P<0.01. These data are highlighted in 





























Figure  10.1 Maximum intra-ventricular pressure measured during ischaemic arrest as 
an indication for ischaemic contraction (n=6)  
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Recovery of heart rate and LVDP were measured during the reperfusion period at 5 to 
10 minutes intervals and the values were normalised to the control period. The heart rate 
recovery data are shown in Figure  10.2; slightly slower recovery in heart rate was 
observed in both EAC and STH2 compared to the LAC group, but after 30 minutes of 
perfusion the three groups become similar. Recovery of LVDP showed significant 
improvement during reperfusion in the EAC group compared with the STH2 group 
(Figure  10.3). 


























Figure  10.2 Heart rate recovery during reperfusion between the three groups 
demonstrating the difference in heart rate recovery at early perfusion between the 
EAC group and the LAC group. 
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Figure  10.3 LVDP recovery during reperfusion between the three group 
demonstrating the difference in contraction recovery at early perfusion and later 
between EAC and STH2 group. 
10.4  Discussion and conclusion 
After establishing the exact mode of action of esmolol, we aimed to follow a systematic 
method of design for a cardioplegic solution that would fit the criteria we previously 
established to determine the suitability of any cardioplegia. We aimed to use agents with 
known protective effects against ischaemia and, by targeting multiple cellular targets to 
induce arrest, we were able to use smaller doses of each pharmacological agent (Fallouh 
et al. 2009). This systematic approach yielded the combination of esmolol and 
adenosine. Blocking the sodium and the calcium channels by esmolol along with 
hyperpolarising the AV node by adenosine should induce arrest without depolarisation. 
We can, therefore, consider this combination as a non-depolarising cardioplegic 
solution. Our aim in these studies was to examine the concept of whether we can 
develop a cardioplegic solution, which can offer better protection against ischaemia. 
Due to time limitations, further studies of other potential agents that might enhance 
other myocardial protection (such as magnesium or BDM) were not investigated. It does 
appear, however, that the combination does offer a viable option as a polarising 
cardioplegic solution in the Langendorff perfused rat heart compared with the current 
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gold standard cardioplegic solution. It also was comparable to the effect of a lidocaine 
and adenosine combination; this solution was shown to be superior to STH (Dobson and 
Jones 2004; Corvera et al. 2005) with the potential possibility of lidocaine accumulation 
if used liberally in at high concentrations (Corvera et al. 2005; Fallouh and Chambers 
2007). Esmolol and adenosine combination can overcome this issue by offering a safe 
and effective polarising cardioplegic solution with superior myocardial protection. 
Further work will be conducted to expand the potential of this adenosine-esmolol 
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